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Abstract
The importance of inorganic nitrogen oxides has been known since 800AD.
However, it was not until the 1980s that major scientific advances were made in this
area of clinical science. Since the finding that NO released from smooth muscle
vascular endothelium has vasodilatory properties, there has been a surge in research
designed to further elucidate the biological roles of this free radical.
Enzyme-dependent and enzyme-independent mechanisms ofNO generation have
been observed in human skin. NO generation by both mechanisms increases
following ultraviolet radiation (UVR). In vivo murine data suggests that NO has an
anti-apoptotic role in human skin following UVR.
In the work presented in this thesis I have shown that zeolite NO (Ze-NO) is an inert
topical NO donor which releases physiologically relevant concentrations ofNO. The
NO released by Ze-NO induces minimal cutaneous inflammation, in contrast to
earlier NO donors investigated. I provide evidence to show that NO is stored in the
form ofNO-related products in human skin and sweat on the skin surface. NO is
released from the products within 30 minutes of exposure to UVR. I provide
preliminary in vivo human data which suggests that NO is acting anti-apoptotically in
human skin following UVR. NO had no significant effect on DNA damage or repair
following UVR. Finally, I provide evidence that a control mechanism for the
upregulation of iNOS exists in human skin in the form of arginase and the urea cycle.
In order to develop our understanding of the role ofNO in human skin, all the work
presented in this thesis has been carried out in vivo in human subjects. NO has
complex pleiotropic actions which depend upon the concentration ofNO, the target
cell and the microenvironment. In vivo clinical research, using physiologically
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1. CHAPTER 1 - GENERAL INTRODUCTION
Chapter 1
1.1. The history ofnitric oxide
Knowledge of the beneficial and/or physiological effects of inorganic nitrogen
oxides has a long and rich history. The most ancient example is the use of nitrate
(N03 ) salts to cure foods, this colours meats and also acts as an antibacterial against
botulism(Binkerd and Kolari, 1975). Documents from around 800AD suggest that
NO3" and nitrite (NO2) were used in Chinese traditional medicine to relieve 'acute
heart pains, and cold in the hands and feet'(Gladwin et al., 2005). In 1865 Brunton
discovered the vasodilator 'amyl nitrite' as a treatment for angina(Lauder Brunton,
1867). From the time of discovery of the vasodilatory properties of the organic
nitrates and nitrites, it took more than 100-years to elucidate their mode of action at
the molecular level. The vasodilator action of these 'nitrovasodilators' is now known
to be mediated by the release of nitric oxide (NO).
The growth of interest in the biological effects ofNO began in 1980. Furchgott and
Zawadzki found that strips of aorta with intact endothelium relaxed in response to
acetylcholine, but constricted in response to the same agonist when the endothelium
had been rubbed off, indicating an essential role for the endothelium in smooth
muscle vascular reactivity(Furchgott and Zawadzki, 1980b). The molecule mediating
this effect was termed endothelium-derived-relaxing-factor (EDRF). In 1987
Furchgott and Ignarro independently proposed that EDRF is NO(Ignarro et al.,
1987a;Furchgott, 1986), subsequently Ignarro and Palmer showed that EDRF and
NO are indistinguishable based on key chemical properties(Ignarro et al.,
1987c;Palmer et al., 1987). Studies have shown that NO released from the
endothelium diffuses into vascular smooth muscle, where it activates soluble
guanylyl cyclase by binding to its haem group, which results in increased cyclic
guanosine monophosphate (cGMP) levels(Ignarro et al., 1986). Cyclic GMP
activates GMP-dependent kinases and downstream signalling that ultimately
decreases intracellular calcium concentration leading to vasodilation(Ignarro, 1990).
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In 1998 Robert Furchgott, Louis Ignarro and Ferid Murad won the Noble Prize in
Physiology or Medicine, for their work on the role played by NO in regulating blood
pressure and blood flow. The prizes are presented on the 10th ofDecember, the
anniversary of the death of Alfred Nobel, the 19th century Swedish industrialist and
inventor. Ironically, Alfred Noble is best known for the discovery of dynamite,
which he formed by incorporating the now well known NO-donor drug glyceryl
trinitrate into kieselguhr, a porous material consisting largely of silica.
1.2. Free radicalproperties ofNO
Oxygen and nitrogen together comprise over 98% of the air we breathe. Both play a
central role in biology. NO is the simplest compound of nitrogen and oxygen. NO is
a diatomic free radical molecule and is a gas at room and body temperature. As a free
radical NO is a highly reactive molecule within biological systems, reacting with
other free radicals, molecular oxygen and transition metals. NO is soluble both in
water and lipid(Henry et al., 1993), it is therefore, freely diffusible in the
environment of the cell. The reactivity ofNO is related to its redox properties, as is
oxygen, both forming redox couples. Oxygen-derived species are termed reactive
oxygen species (ROS), whereas those derived from nitrogen are termed reactive
nitrogen species (RNS). Some RNS may be useful but can be toxic in excess, for
example NO. Other RNS are probably always damaging, for example nitrogen
dioxide (NO2) and peroxynitrite (ONOO"). The same is true for ROS; superoxide is
often useful (TV), but the hydroxyl radical (OH) is probably always detrimental. It is
the balance between NO and ROS that determines their biological action.
In mammalian blood and tissues NO may react with molecular oxygen to form NO2"
or with O2" to form ONOO", which subsequently isomerises to yield NO3".
Alternatively, NO may react, probably via dinitrogen trioxide (N2O3), with thiols and





Figure 1.1 Potential reactions ofNO in blood and tissues
Despite its structural simplicity, NO has a complex chemistry, endowing the free
radical with wide and varied biological actions. NO is synthesised by a number of
cell types, where it acts as a highly regulated autocrine and paracrine signalling
molecule. The sphere of influence ofNO itself is likely to only extend to several cell
diameters (~100pm) of its origin, on account of its reactive nature. Thus, NO is
often described as a local mediator that does not need complex metabolism for
clearance; it is simply diluted and then oxidised to nitrite and nitrate over time(Miller
and Megson, 2007c).
1.3. Synthesis and transport ofNO
1.3.1. Enzyme dependent NO synthesis
NO is generated by the enzyme nitric oxide synthase (NOS)(Moncada and Higgs,
1993), which catalyzes the conversion of L-arginine to L-citrulline and NO with a
1:1 stoiochiometry(Griffith and Stuehr, 1995). Three different NOS isoforms exist
that are encoded by different genes located on different chromosomes. Two enzyme
isoforms are constitutively expressed (endothelial and neuronal cNOS), whereas one
isoform is an inducible enzyme (iNOS), initially found in macrophages(Knowles and
Moncada, 1994). All NOS isoforms show moderate homology with cytochrome p450
reductase and exist in their active form of homodimers of two subunits with
molecular masses of approximately 135 kDa (eNOS), 150-160 kDa (NNOS) and 130
kDa (iNOS)(Bruch-Gerharz et al., 1998). All isoenzymes require the cofactors
reduced nicotinamide adenine dinucleotide phosphate (NADPH), flavin
mononucleotide (FMN), flavin dinucleotide (FAD), protoporphyrin IX haem,
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tetrahydrobiopterin and calmodulin(Cho et al., 1992;Kroncke et al., 1995a;Nathan
and Xie, 1994). Differences exist in the cellular distribution, regulation and
enzymatic activities of the three NOS isoforms.
The cNOS isoforms, which were first detected in neuronal cells (nNOS) and
endothelial cells (eNOS), are active only after binding of calcium-calmodulin
complexes, and produce picomolar to nanomolar amounts ofNO for short periods of
time (seconds to minutes). NO synthesised by these isoforms usually acts as an
intercellular signalling molecule mediating time-restricted events. cNOS isoforms are
generally regarded as providing regulatory and homeostatic functions such as
limiting ultraviolet-induced epidermal apoptosis, maintaining blood pressure,
inhibiting platelet aggregation and leukocyte adhesion, and promoting
gastrointestinal motility(Abramson et al., 2001).
In contrast to the cNOS isoforms, inducible NOS (iNOS) is regarded as playing a
more pathological role. iNOS is an inducible and Ca independent isoenzyme. iNOS
is transcriptionally regulated and therefore requires de novo messenger RNA and
protein synthesis for its activity(Kroncke et al., 1995b). It is expressed following
stimulation with agents such as proinflammatory cytokines, bacterial endotoxins and
ultraviolet radiation, and generates significantly greater amounts ofNO for
comparatively long periods of time (hours-days)(Kolb and Kolb-Bachofen, 1998a).
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All three NOS isoforms have been isolated in human skin(Baudouin and Tachon,
1996;Becherel et al., 1994;Bull et al., 1996;Sakai et ah, 1996;Wang et ah,
1996;Romero-Graillet et ah, 1996). Expression of nNOS has been found in
keratinocytes and melanocytes, whereas expression of eNOS appears to be restricted
to endothelial cells(Baudouin and Tachon, 1996;Dippel et ah, 1994;Goldsmith et ah,
1996;Romero-Graillet et ah, 1996;Weller, 1997). iNOS has been found to occur in
most cells of the skin, including keratinocytes, Langerhans cells, fibroblasts and
endothelial cells (figure 1.2)(Arany et ah, 1996;Becherel et ah, 1994;Bruch-Gerharz
et ah, 1996;Bull et ah, 1996;Nameda et ah, 1996;Qureshi et ah, 1996;Sirsjo et ah,
1996;Wang et ah, 1996).















1.3.2. NOS, arginase and the urea cycle
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NOS catalyses the hydroxylation of the nitrogen in the guanidine group of L-arginine
producing NO. This incorporates molecular oxygen into NO and L-citrulline. The
byproduct of the reaction, L-citrulline, is recycled back to L-arginine as part of a
modified urea cycle (figure 1.3)(Hecker et al., 1990). This has two functions:
• A secretory role to regenerate L-arginine for NO synthesis.
• An excretory role to eliminate excess nitrogen produced by the cell's
metabolism.
Figure 1.3 The Urea cycle
indicates potential for up regulation by UVR.
NO production following the up-regulation of iNOS is dependent on the availability
of L-arginine, in addition to expression and activity of the cationic amino acid
transporters (CAT), which allow L-arginine transport into cells. Normally, levels of
L-arginine are sufficient for continuous secretory NO biosynthesis. However, it has
been shown that in cytokine-activated endothelial cells, L-arginine supply at
physiological levels can restrict eNOS activity(Suschek et al., 2003a). A tight link
exists between iNOS and the urea cycle. Arginase 1 also competes for L-arginine as
a substrate which it hydrolyses to ornithine and urea as part of the urea cycle (figure
7
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1.3). Substrate competition by arginase 1 has been shown to be effective in down
regulating NO production(Mori and Gotoh, 2000).
1.3.3. Enzyme independent NO synthesis
The tl/2ofNO (0.05-1.18milliseconds)(Borland, 1991;Liu et al., 1998;Vaughn et al.,
2000) is very short, and thus it was initially regarded as having actions only in close
proximity to its site of production. It is now accepted that NO can form additional
bioactive stable carriers/donors in the blood and tissues by reacting with sufhydryl
(SH) groups to form S-nitrosothiols (RSNOs)(Stamler et al., 1992b). These regulate
proteins by S-nitrosation of specific cysteine residues(Hess et al., 2001). A major
proportion of endogenous NO is also inactivated by oxidation to N02~ and the more
stable NO3", this inactivation may be transient as N02~ can itself be recycled into
bioactive NO(Lundberg and Govoni, 2004). These more stable NO carriers/donors
can be considered as biological NO stores, under the heading ofNO-related products
they include: NO3", N02~, RSNOs and N-nitrosoamines (RNNOs).
Nitrite has been shown to act as a signalling molecule in its own right(Bryan et al.,
2005), and can also provide a bioavailable pool ofNO during periods ofhypoxia and
ischaemia(Wink et al., 1996a;Zweier et al., 1995). Low molecular weight RSNOs
exert NO-like activity in v/vo(Ignarro et al., 1981) and circulating RSNOs can release
NO when required(Rassaf et al., 2004).
In human skin the presence ofNO-related products has been demonstrated both in
sweat on the skin surface(Weller et al., 1996) and in the skin itself(Paunel et al.,
2005). Using ex vivo skin biopsy specimens Paunel et al., have shown that ultraviolet
A (UVA) irradiation induces photolysis ofRSNO and N02~ stored in human skin
with subsequent high-output NO formation. This reaches a maximum 20 minutes
after the onset of irradiation(Paunel et al., 2005). Weller et al., have also described
NO generation by sequential reduction of sweat NO3" to N02" and then NO on the
skin surface(Weller et al., 1996). While initially described on the skin surface, and in
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the stomach, this NO3" reductive process may be common to many epithelial and
mucosal surfaces.
1.3.4. NO transport
There are three proposed mechanisms for NO transportation in the bloodstream:
• Compartmentalisation theory - NO remains intact in the blood vessel
for longer than initially believed. NO that diffuses into the vessel lumen
and into the erythrocyte reacts at a nearly diffusion-limited rate with
oxyhaemoglobin yielding methaemoglobin and N03~(Liu et al., 1998).
This reaction is so fast that all available NO would be consumed if
barriers did not exist. Several diffusional barriers exist which are
estimated to decrease the rate ofNO scavenging by intra-erythrocytic
Haemoglobin (Hb) greater than 600-fold:
o Compartmentalisation of Hb within the erythrocyte,
o Erythrocyte membrane and submembrane limiting the rate of
NO reaction with Hb(Vaughn et al., 2000;Huang et al., 2001).
o An unstirred diffusional barrier around erythrocytes(Liu et al.,
1998;Coin and Olson, 1979).
o Erythrocyte free zone ofplasma along the surface of the
vascular endothelium(Vaughn et al., 1998;Butler et al.,
1998;Liao et al., 1999).
• NO can be transported in blood and tissues in theform ofRSNOs, e.g.
S-nitrosylation of albumin. NO can also bind to cysteine residues in Hb
(SNO-Hb). S-nitrosated haemoglobin and albumin act as stable storage
forms of intravascular NO and as an allosterically regulated delivery
vehicle for NO(Jia et al., 1996;Stamler et al., 1992b). The main
criticism to this theory is the lack of evidence for the existence of
significant amounts of S-nitrosated proteins in the human circulation.
Also, in contrast to nitrite, there are no detectable arterial-to-venous




• The most recent theory is that NO is generatedfrom NO2 by simple
reduction, this can occur in both blood and tissues(Cosby et al., 2003).
Nitrite is regarded by many as an ideal vascular storage pool for NO, it
is present at fairly high levels in blood and is more stable than
NO/SNOs. With sufficient oxygen the predominant reaction product is
NO3", however NO is favoured when oxygen falls, creating an
autoregulation system. The demonstration of artery-to-vein gradients of
NO2" in the human circulation and increased consumption ofMV
during exercise stress, provide evidence to support NO2" as an NO
transporter(Gladwin et ah, 2000b). It is proposed that release ofNO
occurs following the reaction of deoxyHb (HbFe11) with NO2",
vasodilation occurs as Hb unloads oxygen to 50% saturation.
Xanthinoxidoreductase, MetHb and NO3" can also liberate NO. Nitrite
fits the requirements for a physiological mediator of hypoxic
vasodilation because it maximally reacts with Hb at 50% Hb saturation
(P50 Hb). This oxygen tension is significantly higher than that required
for SNO-Hb deoxygenation(Gladwin et ah, 2006).
1.4. Biological roles ofNO
1.4.1. General
NO is well known for its divergent effects, these effects ofNO are dependent on a
number of factors, including: the source ofNO, the redox form and pH of the
microenvironment, and the target cells in tissue. NO has an astounding range of
biological roles including modulation of vascular tone, memory formation and
inflammation(Moncada and Higgs, 1993;Southam and Garthwaite, 1993;Schmidt
and Walter, 1994;Nussler and Billiar, 1993). NO often achieves these effects by
binding to the haem group of the soluble form of the enzyme guanylate cyclase, but
rarely through irreversible chemical modifications of other molecules. NO is a prime
example of a molecule which may normally be useful but is toxic in excess.
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The most studied actions ofNO are in the cardiovascular system. Extremely low
(pico-nanomolar) amounts ofNO are continuously produced by eNOS in the
endothelial cells that line the lumen of blood vessels. This homeostatic NO
production is responsible for vasodilatation, vascular smooth muscle cell inhibition,
inhibition ofplatelet aggregation and adhesion and inhibition of inflammatory cell
activation and monocyte activity(Miller and Megson, 2007b).
The properties and cellular targets ofNO at higher concentrations are markedly
different to those ofNO at lower concentrations. Under oxidative stress, NO rapidly
reacts with superoxide to form ONOO". Under these circumstances NO is highly
cytotoxic, a feature that is exploited by inflammatory cells in response to invading
pathogens by expressing iNOS in concert with activation ofNAD(P)H oxidase to
generate NO and superoxide forming ONOO", which has a highly cytotoxic and
cytostatic role (figure 1.1). At high concentrations, NO also reacts with molecular
oxygen, generating nitrosating species capable of regulating protein and cell
function(Gow et al., 2004). NO, endogenous RSNOs and ONOO" can have an
inhibitory impact on cellular respiration through interaction with complexes in the
respiratory chain(Beltran et al., 2000;Brown and Borutaite, 2004). High
concentrations ofNO and related species can also mediate apoptosis in inflammatory
cells(Taylor et al., 2003).
1.4.2. NO and inflammation
The pleiotropic actions ofNO are exemplified when studying the role it plays in
inflammation. NO has many anti-inflammatory properties, such as the effects that it
has on vascular permeability: NO diminishes endothelial permeability(Granger and
Kubes, 1996) and NO donors have been found to reduce oedema formation in
various experimental models(Hinder et al., 1999). NOS inhibitors can exacerbate
oedema formation(Mundy and Dorrington, 2000). Leukocyte and platelet adherence
to the endothelium are inhibited by NO(Kubes et al., 1991;Clancy et al., 1992), as is
the production of superoxide anions by leukocytes(Clancy et al., 1992). In addition
NO inhibits macrophage degranulation(Clancy and Abramson, 2000).
11
Chapter 1
Evidence also exists for the pro-inflammatory properties ofNO: in experimental
models of inflammation it has been shown to promote carrageenin-induced oedema
in the mouse footpad(Ianaro et al., 1994), it also induces vasodilation in the
neurogenic inflammatory reaction of the rat hindpaw skin to topical application of
mustard oil(Lippe et al., 1993).
1.4.3. NO in human inflammatory diseases
1.4.3.1.Lupus erythematosus
NO has been implicated in numerous inflammatory diseases. Weinberg et al.,
demonstrated that the murine model of lupus (MRL/lpr mice) develop a spontaneous
autoimmune disease resembling systemic lupus erythematosus (SLE). MRL/lpr mice
excrete significantly higher concentrations of urinary NO2"/ NO3" as an indicator of
increased NO generation/Weinberg et al., 1994). MRL/lpr mice fed a diet rich in L-
arginine develop more severe nephritis, although iNOS_/~ mice are not protected from
the development of arthritis and nephritis/Peters et al., 2003). An upregulation of
iNOS has been demonstrated in vascular endothelium from patients with
SLE(Belmont et al., 1997). An increase in serum NO2" has been shown to be
proportional to disease activity and double stranded DNA Ab titres in human SLE,
the strongest correlation is between serum NO2" levels and renal disease/Peters et al.,
2003).
1.4.3.2.Arthritis
iNOS expression has been shown to be upregulated in the synovium of both
rheumatoid arthritis (RA) and osteo arthritis (OA) patients/Sakurai et al.,
1995;McInnes et al., 1996;Grabowski et al., 1997;Armour et al., 1999). iNOS is
localised mainly to fibroblasts in the synovial membrane ofRA patients, evidence
suggests that it upregulates tumour necrosis factor a (TNFa) which subsequently




As with many diseases the role ofNO in systemic sclerosis (SSc) may be seen as
paradoxical. Impaired basal NO production may contribute greatly to the
development of SSc vascular disease by enhancing vasospasm, platelet aggregation,
upregulation of endothelial and leukocyte adhesion molecules and increasing
vascular wall thickness. Deficient NO release from SSc vascular endothelium in vitro
has been demonstrated (Freedman et al., 1999;Romero et ah, 2000). In contrast, an
increase in iNOS expression has been demonstrated in lesional skin of SSc
patients(Yamamoto et ah, 1998;Cotton et ah, 1999), and an increase in circulating
NO3" in SSc correlates with markers of endothelial damage and disease
activity(Yamamoto et ah, 1998). In SSc, endothelial injury seems to reduce eNOS
and increase iNOS activity, resulting in a vasconstricting and proinflammatory
environment in association with tissue damage(Matucci and Kahaleh, 2002).
1.4.3.4.Atherosclerosis
It is now widely recognised that there is an inflammatory component to the
pathogenesis and progression of atherosclerosis(Ross, 1999). Recruitment of
inflammatory cells is the major driving force behind plaque development. Apoptotic
macrophages are present in atherosclerotic plaques in both human and animal disease
models(Ludewig et ah, 2002). iNOS has been demonstrated in human atherosclerotic
plaques(Buttery et ah, 1996). The process of resolution of inflammation involves the
phagocytosis of apoptotic cells, thus preventing any further initiation of a
proinflammatory response (figure 1.5). Apoptosis may represent a mechanism for
atherosclerotic plaque regression. NO is a promising candidate for this pathway
because, as well as having pro-apoptotic actions it has several other powerful
antiatherogenic characteristics including a powerful inhibitory effect on platelet and
inflammatory cell activation(Shaw et ah, 2005). L-arginine administration to
hypercholesterolaemic rabbits increases the number of apoptotic macrophages in
intimal lesions three-fold, this is associated with plaque regression(Wang et ah,
13
Chapter 1
1999). These observations suggest that manipulation of the NOS pathway may
represent a therapeutic approach for atherosclerosis.
1.4.3.5.Asthma
The role ofNO in asthma is of interest as recent evidence suggests more complex
interactions than were initially observed. These observations are comparable to those
made for psoriasis, in both diseases internal feedback control mechanisms, involving
the activity of arginase (figure 1.4), determine tissue NO levels and pathogenesis.
Initial observations revealed an increase in NO in the exhaled air of asthmatics,
which was thought to be a marker of airway inflammation(Alving et al., 1993;Saleh
et al., 1998). Conflicting data exists for the role of iNOS in a murine asthma model:
one group suggest that acute inhibition of iNOS activity has no effect(Feder et al.,
1997), whereas a second suggest inhibition of iNOS activity suppresses airway
inflammation(Trifilieff et al., 2000), and finally a third group show that iNOS
inhibition exacerbates airways inflammation(Blease et al., 2000).
Keller et al., suggest a hypothesis for iNOS expression in experimental asthma which
stems from the presence of endotoxin lipopolysaccharides (LPS) (figure 1.4). LPS is
a cell wall component of gram-negative bacteria, which signals through toll-like
receptor 4 (TLR4) and leads to up-regulation of iNOS activity(Wagner et al.,
1983;Stuehr and Marietta, 1985). LPSs are ubiquitous in the environment and found
in household dusts allergens and allergen extracts(Michel et al., 1991;Gereda et al.,
2000). After allergen inhalation, two enzymatic pathways, iNOS and arginase 1, are
activated. The arginase 1 pathway is activated by type 2 cytokines released from
allergen-driven T helper 2 (Th 2) cells, whereas LPS activate the iNOS pathway.
L-OH Arginine, a by product of the conversion of L-arginine by iNOS, inhibits
arginase 1, whereas arginase 1 depletes L-arginine and generates polyamines that
limit NO production and down regulate iNOS expression, respectively(Bronte et al.,
2003;Meurs et al., 2003). Both pathways are activated and are reciprocally
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downregulated, therefore it is likely that L-arginine concentrations are at low levels
following allergen inhalation. It has been shown that iNOS-dependent catabolism of
L-arginine at low levels favours the production of ONOO , known for its
proinflammatory actions(Xia and Zweier, 1997;Xia et ah, 1998). In addition low
local levels of NO have been shown to promote the expression of proinflammatory
proteins including COX2 and IL-6(Connelly et ah, 2001).
NO and ONOO-
Inflammation
Figure 1.4 Role of lipopolysaccharides, iNOS and arginase I in airway inflammation
AdaptedfromiKeller ct ah, 2005)
1.4.4. NO and the resolution of inflammation
Recent studies have revealed that NO can modulate apoptosis in a variety of cell
types, including human inflammatory cells(Taylor et ah, 2003). Macrophages were
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the first cell type in which NO mediated apoptosis was demonstrated(Sarih et al.,
1993;Albina et ah, l993;von Knethen et ah, 1999). In addition, a pro-apoptotic effect
ofNO has been demonstrated in neutrophils(Ward et ah, 2000;Singhal et ah,
1999;Fortenberry et ah, 1999;Taylor et ah, 2001) and eosinophils(Beauvais et ah,
1995). NO has a bi-phasic effect on apoptosis in many cell types, this has been
shown in neutrophils, where NO may also have an anti-apoptotic potential. Low
concentrations ofNO generated from the spontaneous NO donors, spermine/NO
(SPER/NO) and diethylamine (DEA/NO), reduce the rate of neutrophil
apoptosis(Taylor et ah, 2003). The same study also demonstrated that a different NO
donor, GEA-3162, at equivalent concentrations, produced no inhibition. GEA-3162
decomposes to generate NO and O2" which then forms ONOO", suggesting that the
pro- or anti-apoptotic effects ofNO may be governed by the specific NO-related
species generated.
Apoptosis of inflammatory cells is a highly regulated process whereby cellular death
occurs without the disruption of the cell membrane, and subsequent release of the
pro-inflammatory and histotoxic contents of the dying cell(Haslett, 1997). Apoptotic
cells are instantly recognised and ingested by phagocytes, such as macrophages,
using mechanisms that down-regulate pro-inflammatory mediator release, and
increase the release of agents with anti-inflammatory potential from the ingesting
cell(Meagher et al., 1992;Fadok et al., 1998;Liu et al., 1999). Apoptosis represents a
non-inflammatory mechanism to remove potentially damaging pro-inflammatory
cells from the site of inflammation, it is critical to the successful resolution of the
inflammatory response. Chronic inflammation is frequently characterised by a failure
ofmyelocytic cells to undergo apoptosis, or of phagocytes to remove apoptotic cells.
Evidence suggests that NO is particularly relevant in the resolution of inflammation.
Fligh concentrations of iNOS derived NO synthesised in macrophages (phagocytes),
induce apoptosis in neighbouring cells. Apoptotic cells are subsequently recognised
and ingested by phagocytes, thus promoting the resolution of inflammation.
Conversely, low concentrations ofNO produced constitutively by eNOS in




Figure 1.5 NO and the resolution ofinflammation
Adaptedfrom (Taylor et a I., 2003)
1.4.5. NO in skin homeostasis
The skin vascular system is in a constant state of active regulation due to the
generation ofNO(Lowenstein and Snyder, 1992). Small pulses of NO are produced
via eNOS activity in the endothelial cells of skin vessels, which results in smooth
muscle relaxation(Anggard, 1994). It has been demonstrated that NO is involved in
maintaining resting cutaneous blood flow, as the injection of intradermal eNOS
antagonists impair local skin circulation(Goldsmith et al., 1996).
NO has been shown to play a role in cutaneous melanogenesis, evidence exists to
show that NO synthesis by nNOS and subsequent cGMP production in melanocytes
is required for ultraviolet B (UVB)-induced melanogenesis(Romero-Graillet et al.,
1996). In addition NO is involved in the control of keratinocyte proliferation and
differentiation(Krischel et al., 1998), and in the regulation of hair follicle





1.4.5.1.NO and responses to environmental challenges
NO plays a major role following ultra-violet radiation (UVR) in the development of
erythema(Warren, 1994), oedema(Teixeira et al., 1993) and melanogenesis(Romero-
Graillet et al., 1996;Romero-Graillet et al., 1997) (Chi.6).
NO is responsible for forming a protective antimicrobial barrier on the skin surface.
Nitrate present in sweat on the skin surface is reduced by bacteria to produce N02~,
which is then reduced in acidic conditions to produce NO(Weller et al., 1996).
Several pathogens such as Escherichia coli, Candida albicans and mycobacteria
have been shown to be sensitive to the cytotoxic effects ofNO, its generation on the
skin surface is thought to regulate the growth of skin commensal organisms and
prevent infection with skin pathogens(Bruch-Gerharz et al., 1998).
1.4.6. NO in skin disease
With the advent of immunostaining for iNOS, iNOS protein has been demonstrated
immunohistochemically in many inflammatory dermatoses including:
psoriasis(Kolb-Bachofen et al., 1994;Sakai et al., 1996), atopic dermatitis(Rowe et
al., 1997;Clancy et al., 1998) and lupus erythematosus (LE)(Clancy et al., 1998). The
iNOS enzyme is consistently found in the dermis and basal epidermis of psoriatic
plaques(Bruch-Gerharz et al., 1996;Rowe et al., 1997), and the characteristic
erythema seen clinically, indicates vasodilatation and thus presumably biologically
significant NO production.
1.4.6.1.Psoriasis
Measurements with a chemiluminescence meter from the surface ofpsoriatic plaques
show elevated NO release(Ormerod et al., 1998), and serum N02~, an indicator of
systemic NO production, is elevated in psoriatics with active disease(Tekin et al.,
2006). However, as is often the case with NO, the role it has in the pathogenesis of
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psoriasis is more complex than can be explained by a simple increase in NO
production.
iNOS is invariably expressed in keratinocytes from psoriatic skin lesions, this
suggests an influence ofNO on keratinocyte proliferation and differentiation. Such
an effect is demonstrated by the maintenance of normal human keratinocytes in the
presence ofNO donors for prolonged periods of time, mimicking an increased local
NO production(Krischel et al., 1998). Interestingly, NO has been found to exhibit a
biphasic effect on keratinocyte proliferation and differentiation. At low NO donor
concentrations a significant increase in keratinocyte proliferation was observed,
whereas at higher concentrations - comparable to iNOS-mediated synthesis rates -
induction of keratinocyte differentiation was detected, with no cytotoxic effect on the
cells(Krischel et al., 1998). These findings demonstrate the involvement ofNO in the
regulation of epidermal growth and development. It is postulated that this biphasic
role ofNO in the control of keratinocyte proliferation and differentiation is active in
psoriasis. iNOS and subsequently NO are elevated in psoriatic plaques, however
arginase is also upregulated. Arginase competes with NOS for L-arginine which
results in an elevation in NO that is sufficient to induce keratinocyte proliferation but
not differentiation(Bruch-Gerharz et al., 2003).
1.4.6.2.Wound healing
The healing process requires an intricate interaction between inflammatory cells,
biochemical mediators including growth factors and extracellular matrix molecules,
and microenvironmental cell populations(Albina et al., 1990;Yamasaki et al., 1998).
NO has been shown to play a major role in wound healing(Frank et al., 2002).
Reduction in the levels ofwound NO by gene knockout or pharmacological
inhibition results in impairment ofwound healing, as evidenced by increased closure
time, lower wound breaking strength and decreased collagen deposition(Schaffer et
al., 1999). Conversely, supplementation with L-arginine, increases the healing of
wounds(Seifter et al., 1978). This augmentation ofwound healing is not seen in NOS
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knockout mice, further underlining the importance ofwound NO synthesis from L-
arginine(Shi et ah, 2003). In addition, transfection of iNOS cDNA into wounds
results in marked increases in collagen deposition(Thornton et ah, 1998;Yamasaki et
ah, 1998). Recent evidence suggests that NO applied in the form of an acidified
nitrite NO donor, can augment wound healing in normal and diabetic mice. However,
the effects of this preparation are dependent both on the time of application after
wound healing and the concentration of topical NO donor. Application of acidified
nitrite immediately after wounding impairs healing, whereas application on day three
after wounding results in significant healing(Weller and Finnen, 2006b).
1.4.6.3.Infectious skin disease
NO synthesised at high concentrations by iNOS, has been shown to eliminate
intracellular pathogens including Mycobacterium tuberculosis, M. Leprae,
Leishmania species, Trypanosoma cruzi and Plasmodiumfalciparum and also to
block viral replication(Liew and Cox, 1991;Liew et ah, 1991;Scharton-Kersten et ah,
1997;Stenger et ah, 1996). Most cell types express iNOS, however epithelial cells of
the lung, the liver, the gastrointestinal tract and the skin, which act as immunological
barriers, appear to use this mechanism as a first line of defence.
Weller et al., provide data supporting an antimicrobial effect ofNO in the skin.
Acidified NO2" cream, which releases NO via the intermediate N2O3, was used
successfully as a treatment for tinea pedis(Weller et ah, 1998). More recently this
topical treatment has also been successful in treating onychomycosis, > 90% of
patients became culture negative for Trychophyton rubrum following treatment with
acidified NO2". S-nitrosothiols, formed by nitrosation of nail sulphur residues, were
shown to be the active component(Finnen et ah, 2007). Acidified NO2" exploits the
nature of the nail barrier and utilizes it as a means of delivery ofNO/nitrosothiol-
mediated antifungal activity. Thus what is commonly regarded as the principal
obstacle to therapy in the nail becomes an effective delivery mechanism.
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1.4.6.4.Inflammatory or immune-mediated skin disease
It is thought that high-output NO synthesis is critical for immunological reactions in
human skin. In vitro experiments have demonstrated that interleukin-8 (IL-8),
interferon-y (IFN-y), TNF-a and interleukin-ip (IL-ip) are potent synergistic
inducers for iNOS expression in human keratinocytes(Bruch-Gerharz et al., 1996). It
is also hypothesised that aberrant upregulation of iNOS following UVR exposure, is
involved in the pathogenesis of cutaneous lupus erythematosus (cLE)(Kuhn et al.,
1998). The histologic changes of cLE include keratinocyte apoptosis and
inflammation, two processes which are known to be influenced by NO.
It has been demonstrated that NO can be produced in Langerhans cells of human
skin(Qureshi et al., 1996). It is thought that NO may affect Langerhans cell functions
such as antigen presentation and cytotoxicity, and may also be used for the functional
regulation of adjacent keratinocytes and melanocytes. Upregulation/induction of
iNOS expression has been shown in murine Langerhans cells and keratinocytes
during contact hypersensitivity reactions in mice(Ross et al., 1998).
iNOS expression has been shown in dermal microvascular endothelial cells. In
inflammatory processes, the regulation of leukocyte trafficking involves a complex
interplay of adhesion molecules and chemokines, with cytokines produced by both
leukocytes and endothelial cells(Baggiolini, 1998;Suschek et al., 1993). Evidence
indicates that iNOS expression and concomitant increases in NO production in
endothelial cells modulate lymphocyte adhesion as well as leukocyte
trafficking(Khan et al., 1996).
NO may regulate important humoral and cellular responses in innate immune and
inflammatory processes throughout the skin. NO may also be implicated in the
pathogenesis of various inflammatory and immune-mediated skin diseases. It is
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known that NO can exert both pro-inflammatory and anti-inflammatory properties,
even in parallel, depending on the cellular context, and the type and phase of the
inflammatory and cellular immune response(Kolb and Kolb-Bachofen,
1998b;Kroncke et al., 1997). In vivo research in human subjects is vital ifwe are to
advance our understanding of the roles ofNO in inflammatory processes. The human
skin is relatively accessible, which makes it an ideal organ in which to further
elucidate the role ofNO in these processes in both normal and disease states.
1.5. NO stores
1.5.1. Evidence ofbiological activity
The historical view ofNO has been that it can only act in a paracrine manner on
neighbouring cells because of its very short half life. However, more recent studies
have suggested that the bioactivity ofNO in blood in fact can be conserved, thereby
allowing for more distal and sustained effects:
• SNO-Hb acts as a form of bioactive NO(Jia et al., 1996).
• NitrosylHb and NO2" act as potential sources ofNO(Gladwin et al.,
2000a).
• NO itselfmay remain active in the blood stream longer than originally
assumed(Rassaf et al., 2002c).
• RSNO derivatives ofplasma proteins may conserve/transport
NO(Rassaf et al., 2002c;Rassaf et al., 2002b;Stamler et al., 1992a).
Conservation of the bioactivity ofNO is enabled by the formation ofNO-related
products, these storage forms ofNO include: NO3", NO2", RSNOs and RNNOs.
Lundberg et al., have shown that following ingestion of a N03 -rich meal (1 Omg/kg
sodium NO3) there is a rise in saliva, plasma and urine NO3" concentrations, with
subsequent increases in salivary and plasma RSNO, and plasma NO2"
concentrations(Lundberg and Govoni, 2004).
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1.5.2. Individual NO-related products
1.5.2.1.Nitrate (NO3)
Plasma NO3" levels are determined by dietary intake of NO3" and by endogenous NO
production. Diet is the main source ofN03~, vegetables form 60-80% of the daily
NO3" intake of a typical western diet(Spiegelhalder et al., 1976). The main
endogenous source ofNO3" is the L-arginine-NO pathway. An entero-salivary
recirculation pathway exists for NO3", 25% of all circulating NO3" is taken up by the
salivary glands and secreted in saliva, the resulting salivary NO3" concentration is ten
times higher than that in plasma. (Lundberg et al., 2004) (figure 1.6). Ingested NO3"
is absorbed proximally from the gastrointestinal tract into the blood stream where it
mixes with endogenously synthesised NO3". Peak plasma concentrations are seen
within 60 minutes ofNO3" ingestion(Lundberg and Govoni, 2004), the t\a ofNO3" in
plasma is in the order of 5 - 7 hours(McKnight et al., 1997). It was thought for a long
time that human cells can not metabolise NO3", however recent evidence has shown
that a mammalian functional nitrate reductase does exist(Jansson et al., 2008). Oral
commensal bacteria reduce salivary NO3" to NO2", on entering the acidic
environment of the stomach NO2" reacts with stomach acid releasing NO(Benjamin
et al., 1994;Modin et al., 2001). Reduction ofNO2" can also occur: in the oral
cavity(Duncan et al., 1995), on skin(Weller et al., 1996), in urine(Lundberg et al.,
1997) and systemically in blood and tissues.
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Figure 1.6 The entero-salivary circulation ofnitrate
Adaptedfrom(Lundberg et al., 2004)
1.5.2.2.Nitrite (NOf)
There are three sources ofN02~ in mammals:
• An oxidation product ofNOS.
• Dietary, N02" is found as a food additive in meat to prevent botulism
and to enhance its appearance(Lundberg et al., 2004).
• Generated from commensal bacteria in the digestive system by NO3"
reduction.
The majority (80-90%) of plasma N02~ originates from eNOS activity, therefore it is
often regarded as a biomarker for eNOS fimction(Kleinbongard et al., 2003).
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There is a relatively wide range of reported human basal plasma N02~ concentrations,
from 75nM to 26pM(Pelletier et al., 2006;Gorenflo et al., 2001) (table 1.1).
Explanations for such a wide range in plasma N02~ include: the rapid metabolism of
NO2" to NO3", variations in blood sampling and sample processing, and
methodological problems in analysis (some methods are not sensitive enough,
analysis may also be affected by proteins, varying redox conditions, contamination
with lib and trace contamination with N02~ during processing).
Plasma NOT levels are higher than those ofRSNOs. It was initially suggested that
RSNOs are the main carriers ofNO in the circulation, however there is increasing
evidence that N02" is the more important NO-related product (Lundberg et al., 2004).
A number of groups have published evidence which suggest that N02" is a major
intravascular storage pool for NO:
• NO2" is present in relatively high concentrations in
plasma(Kleinbongard et al., 2003) and tissue(Rodriguez et al., 2003).
• N02" is relatively stable as it is not reduced by cellular reductants that
affect RSNOs and NO(Gladwin et al., 2002).
• The reaction rate ofN02~ with haem proteins is 10,000 times less than
that ofNO(Dejam et al., 2004).
During conditions of ischaemia and acidosis, N02" can release NO by non-enzymatic
mechanisms(Zweier et al., 1995):
• NOT can form nitrous acid, which can react with N02" again or an
electron donor (such as ascorbate) to form N203. Dinitrogen trioxide can
then nitrosate thiols or, in the presence of an electron donor, produce
NO gas(Wink et al., 1996a).
• Xanthinoxoreductase, which is abundant in vascular tissue, can reduce
N02" to NO(Millar et al., 1998).
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Nitrite has been shown to act as a signalling molecule in its own right(Bryan et al.,
2005). Physiological data also suggests that NO2" has direct effects, inhaled NO can
have vasodilatory effects not only locally in the pulmonary circulation but also in
peripheral tissues, this is associated with an increase in N02~(Cannon, III et al.,
2001;Fox-Robichaud et al., 1998;Takahashi et al., 1998).
1.5.2.3.Nitrosothiols (RSNOs)
NO can react with a number ofmolecular targets in the blood following reaction with
molecular oxygen or reactive oxygen species to form NO2, N2O3, or ONOO". Unlike
NO, these species are nitrosating or nitrating agents that can react with aromatic
compounds, amines, alcohols and thiols to form C-, N-, O- and S-nitroso
species(Rassaf et al., 2002c). Products ofNO oxidation (NOx) rapidly react with SH-
groups, e.g. in proteins, to form RSNOs like: S-nitrosoalbumin, S-nitrosoglutathione,
or S-nitroso-L-cysteine. Albumin, the principle plasma protein, reacts with NO to
form S-nitrosoalbumin (SNOAlb), this confers NO+ (nitrosonium), NO" (nitroxyl),
and NO-donating properties to this molecule(Rassaf et al., 2002a). Human albumin
contains a single free SH-group in Cys-34, which binds to NO(Kashiba-Iwatsuki et
al., 1997).
There is no consensus as to the true physiological levels of RSNOs, published data
suggests levels in human plasma ranging from 6.3nM to 7pM(Lundberg and Govoni,
2004;Stamler et al., 1992a) (table 1.1). There is general agreement thatN02_ is
present in human plasma in greater levels than RSNOs. Similarly to the measurement
ofNO2", the variation in published RSNO concentrations may have their origin in the
different methodological approaches used and associated technical difficulties,
including artifactual RSNO formation, inherent to trace level analysis of NO-related
products.
The biological effects ofRSNOs resemble NO but their tj/2 is much longer, effects
include: vasodilatation(Keaney, Jr. et al., 1993), smooth muscle relaxation(Iversen et
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al., 1994;Jansen et al., 1992), and inhibition of platelet aggregation(Radomski et al.,
1992;Simon et al., 1993).
1.5.2.4.N-nitrosamines (RNNOs)
Little is known about the reaction sites ofNO other than thiols. It is known that
RNNOs are generated endogenously during infections and inflammatory
processes(Ohshima and Bartsch, 1994). In the acidic environment of the stomach,
RNNOs are formed due to the reaction ofNO2" with amino groups of food
constituents(Lijinsky, 1980) and secondary amines. Irrespective of whether they are
taken up during occupational exposure, ingested with the diet(Lijinsky, 1999), or
formed endogenously, most low molecular weight RNNOs are potentially mutagenic
and have been associated with an increased risk of cancer(Ohshima and Bartsch,
1994).
1.5.3. Quantification ofNO-related products
Many different methods to measure plasma NO-related products have been proposed,
due to the rapid metabolism ofMV in blood and the difficulties in its analytical
determination, an agreement on which is the most reliable method has not yet been
reached. The result of such disagreement is a variation in published data from
different groups regarding the concentration ofNO-related products in human
biological samples (table 1.1).
Existing methods for the quantification ofNO-related products include:
• The Griess assay - a colorimetric method used to quantify NO2", it was first
described by Peter Griess in 1858. Sulphanilic acid is added to a NO2"
containing sample forming a diazonium salt. An azo dye is then added (N-l-
napthylethylenediamine HCL) which couples with the diazonium salt to form
an azo dye with a red pink colour(Griess, 1879).
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• The Saville assay - this was originally described for the quantification of
thiols, it is a technique based on mercuric chloride (HgC^) - induced
cleavage ofRSNOs to release NO2", which is then quantified using the Griess
assay (Saville, 1958).
• Electron paramagnetic resonance (EPR) spectroscopy - has been shown to be
useful for determination ofNO in metal complexes or haem proteins(Henry
and Guissani, 2000). It can be applied in vivo, however it does not detect any
other NO-related products and it has a low sensitivity.
• A more recent approach to NO-related products in biological systems
involves liberation ofmolecular NO from the medium, followed by its
detection via chemiluminescence accompanying its gas phase reaction with
ozone. There are two classes of assays:
o Those employing UV light to liberate NO photolytically. To
distinguish FeNOs from SNOs, inorganic or organic mercury (Hg) is
added. Mercury displaces NO from thiols in the form ofNO2".
Proteins are then desalted in physiological buffers to remove low-
molecular-weight reactants. The quantitiy of SNOs is calculated by
measuring the loss of signal caused by Hg. All SNOs are reactive to
Hg, whereas FeNO is unreactive, therefore the signal loss equates to
the RSNO concentrationMcMahon and Stamler, 1999).
o Those employing chemical reactions. Identification depends on the
differential reaction ofNO-compounds toward a series of chemical
reagents. Triiodide methodology is popular as it enables measurement
ofNO2" and RNNOs as well as SNO and FeNO(Feelisch et al., 2002).
Advocates ofphotolysis suggest the typically lower reported metabolite values
measured using triiodide and other chemical based methods is the result of acid
induced protein damage, and a general lack of understanding as to the chemical
interactions in the mix. It is suggested that triiodide assays are strongly influenced by
sample composition, rather than solely by the identity or quantity ofNO
species(Hausladen et al., 2007). In contrast, those groups favouring chemical assays
argue that harsh photolytic exposure and secondary heating cause a lack of
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specificity for RSNOs, and in biological samples thiols enhance NO release from
NO3" photolysis leading to an overestimation of biological RSNO levels(Dejam et al.,
2003). It is suggested that photolysis not only frees NO from RSNOs but also from
compounds such as NO2", nitrosamine and dinitrosyliron complexes(Rossi et al.,
2001).
The originally documented RSNO concentration in human plasma was 7pMol/L, this
was made by Stamler et al. using a photolytic method of analysis(Stamler et al.,
1992a). The majority of recent studies have disputed these values and suggest levels
in the nmol/L range (table 1.1). Kleinbogard et al. compare three different analytical
methods ofmeasuring plasma NO2", the uniform presence of nanomolar
concentrations (100-600nmol/l) of plasma NO2" was demonstrated in 90% of all
individuals of various mammals including humans(Kleinbongard et al., 2003). The
three methods of analysis compared were:
• Flow injection analysis combined with the Griess assay.
• Reductive gas phase chemiluminescence detection.
• High-pressure liquid chromatography combined with the Griess assay.
I have elected to use a gas phase chemiluminescence based assay for the
quantification ofNO-related products in biological samples, this method has been
selected in view of the arguments presented above, and in particular because:
• There has been recent validation of this method for the quantification ofNO-
related products in biological samples(Feelisch et al., 2002).
• There is favourable comparison of results obtained using this method with
those in the majority of published data.
• The sensitivity of this method for the detection of trace quantities ofNO
(femtomols), making it the method of choice for quantification of low levels
ofNO-related products. This is a factor which is of particular importance




• This method enables quantification of individual NO-related products: N02~,
RSNOs, RNNOs.
1.5.3.1.Gas-phase chemiluminescence detection ofNO-relatedproducts
The concentration ofNCV and various NO-related products is determined after
reductive cleavage by an iodide/triiodide-containing reduction mixture, and
subsequent determination of the NO released into the gas phase by its
chemiluminescent reaction with ozone (O3). NO reacts with O3 to form nitrogen
dioxide (NO2), a proportion of the NO2 arises in an excited state (N02*). On decay to
its ground state NO2* emits light in the near infra-red region, which can be quantified
by a photomultiplier(Clough and Thrush, 1967) (figure 1.7). The intensity of light
emitted is directly proportional to NO concentration^eelisch et al., 2002). NO
concentration of biological samples is determined by comparing the output from the
sample against a standard curve created from N02~ standards.
NO + O3 ^^N02* + O2
N02*^ N02 + hv
Figure 1.7 Gas-phase chemiluminescence reaction ofNO with ozone
Quantification of individual NO-relatedproducts - Individual nitrosospecies can be
quantified without having to change the reduction mixture or experimental
conditions, this is achieved by pretreating samples with group-specific reagents
before analysis (figure 1.8). A biological sample is divided into four aliquots:
• Direct injection into reduction mix (quantifies N02~ + RSNOs + RNNOs).
• Pretreatment with sulfanilamide (quantifies RSNOs + RNNOs).
• Pretreatment with HgCl2/sulfanilamide (quantifies RNNOs + mercury
resistant NO-related products).




Nitrate is stable and not reduced by the iodide/triiodide-containing reduction
mixture. The biological sample is pretreated with a NOT reductase mix. The NO3"
concentration is then determined by subtraction of the peak areas of untreated sample
aliquots from sample aliquots pretreated with NO3" reductase mix.
Nitrite concentration of a biological sample is determined by subtraction of the peak
areas of sample aliquots pretreated with sulfanilamide from that of untreated
aliquots. Sulfanilamide reacts with the NO2" in the solution to form a stable
diazonium ion.
S-Nitrosothiol concentration present in a biological sample is quantified by the
subtraction of the peak areas of sample aliquots pretreated with HgCf/sulfanilamide
from that of sample aliquots pretreated with sulfanilamide. Incubation with HgCf
causes cleavage of the S-NO bond without affecting peak shape or recovery of NO2"
or NO, this reaction forms the basis of the Saville assay(Saville, 1958).
Mercury-resistant NO-related products, which include RNNOs or metal nitrosyls,
are represented by the peak remaining after incubation with HgCf/sulfanilamide.
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Ultraviolet radiation is part of the electromagnetic spectrum (figure 1.9). In 1801
Johann Ritter discovered the UV region of the solar spectrum by showing that
chemical action was caused by some form of energy in the dark portion beyond the
violet(Ritter, 1801). In the previous year, Sir William Herschel had demonstrated the
existence of radiation beyond the red end of the visible spectrum, a component now
known as infrared radiation(Herschel, 1800). Ultraviolet, visible and infrared
radiation, are referred to collectively as optical radiation.
Ultraviolet radiation spans the wavelength region from 400 to lOOnm, the UVR
spectrum is further subdivided into three regions: UVA, UVB and UVC. The idea of
dividing the UV spectrum into spectral regions was first put forward at the
Copenhagen meeting of the Second International Congress on Light, August
1932(Diffey, 2002). The three spectral regions were defined as:
• UVA 400-315nm
• UVB 315-280nm
• UVC 280-1 OOnm
These divisions are arbitrary and differ depending on the discipline involved.






















10 1 10 'ft"* 10
e
10" T-r*--^ 1 103 10+
Wavelength (meters)
200nm 290nm 320nm 400nm
Wavelength (nanometers)
Figure 1.9 UVR within the electromagnetic spectrum
The quality (spectrum) and quantity (intensity) of terrestrial UVR vary with the
elevation of the sun above the horizon. The elevation of the sun depends on the time
of day, day of year, and geographical location (latitude and longitude). The quality
and quantity of solar UV are modified as the sun's rays pass through the atmosphere.
In the stratosphere (-10-15km above sea level) there is absorption by 03 and
scattering by molecules. In the troposphere (0-1Okm above sea level) there is
absorption by pollutants and scattering by particulates and clouds. The attenuation of
UVR in the atmosphere absorbs UV in a wavelength dependent manner, for example
on a summer's day UVB constitutes 6% of the UVR reaching the earth's surface, the
remaining 94% is UVA, UVC is absorbed by O3 and does not reach the surface of
the earth. Although UVB constitutes the smallest proportion of terrestrial UV when
compared with UVA, it is the most effective at inducing erythema.
1.6.1. Radiometric calculation s
The term 'irradiance' relates to the object (human subject) struck by the radiation, it
is expressed as power (W) per m , the irradiance of a UV source is measured using a
radiometer. The time integral of the irradiance is termed the 'radiant exposure', but is
often expressed as 'dose'. The relationship between time, dose and irradiance is
expressed in figure 1.10.
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1000 x prescribed dose (J cm 2)
60 x measured irradiance (mW cm 2)
Figure 1.10 Radiometric calculations
1.6.2. UVR and human skin
The skin is a primary target for UVR. UVR induces several cutaneous effects
including: erythema(Rhodes et al., 2001), immune suppression(Damian et al., 2001),
keratinocyte apoptosis(DANIELS, Jr. et ah, 1961), accumulation of stable p53, DNA
damage(Brash et ah, 1991;Douki et ah, 2003;Kobayashi et ah, 2001;Mouret et ah,
2006;Sheehan et ah, 2002), skin cancer(Brash et ah, 1991;Brash et ah, 1996;Dumaz
et ah, 1993;Ziegler et ah, 1993) and premature ageing(Gilchrest et ah, 1979;Kripke,
1974).
1.6.2.1.Erythema
Erythema formation post UVR is a result of local increases in blood flow in both the
superficial and deep vascular plexus of the dermis(Greaves, 1986). Erythema first
becomes detectable 3-4 hours after exposure, is maximal between 8 and 24 hours,
and persists for more than 48 hours(Anderson et ah, 1991). The abilitiy ofUVR to
elicit erythema in human skin depends strongly on wavelength. A statement that a
subject received an exposure dose of 1J cm"2 ofUVR conveys no information
regarding the likely erythemal effect. Studies show that UVB is orders ofmagnitude
more effective per unit dose (J m"2) than UVA at generating erythema. For example,
the median 'minimal erythemal dose' (MED) at 300nm is 0.025J cm"2 whereas at
360nm it is 32J cm"2(Young et ah, 1998).
1.6.2.2.Measurement oferythema
For many years the term MED has been used as a 'measure' of erythemal radiation.





given. The MED is defined as the lowest UVR that will cause either a just
perceptible redness or redness with a definite border. It is important to remember that
this is a biological measure which is different for each individual, in view of this it
has been suggested that MED should be reserved for use in observational studies in
humans and other animals only.
More recently the term 'standard erythemal dose' (SED) has been proposed, this
refers to erythemal effective radiant exposures from natural and artificial sources of
UVR. One SED is equivalent to an erythemal effective radiant exposure of 100J m"
2(Diffey, 2002). Examples of the use of SED are:
• The ambient diurnal exposure on a clear sky summer day in Europe is
approximately 30-40 SED.
• Four SED would be expected to produce moderate erythema on unexposed
white skin, but little or no erythema on previously exposed white skin.
It is estimated that in skin types I-IV, one SED equates to 1.5-6 MEDs(Diffey et al.,
1997).
1.6.2.3.Apoptosis
The term apoptosis comes from combining the Greek prefix apo-, meaning 'offor
'from' andptosi, meaning 'falling upon or in something', the entire word roughly
translates to 'a falling off of leaves from a tree'. Apoptosis was coined by Kerr et al.,
to differentiate between programmed cell death and necrosis(Kerr et al., 1972). There
are two types of cell death:
• Apoptosis, an active process of single cell suicide, these cells are then
phagocytosed by macrophages thus avoiding inflammation.
• Necrosis is induced by severe external insult, this affects groups of cells and
usually induces an inflammatory reaction.
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UVR induces apoptosis in human epidermal keratinocytes, keratinocytes undergoing
apoptosis are termed 'sunburn cells'. Sunburn cells were first described by Daniels et
al., they are easily identified morphologically in haematoxylin and eosin (H&E)
sections as being isolated epidermal cells with pyknotic nuclei, and shrunken
eosinophilic cytoplasm(DANIELS, Jr. et al., 1961). Their presence suggests that
cellular DNA has been irreparably damaged, it is generally accepted that their role is
to remove UV-initiated potentially mutagenic cells from the skin(Claerhout et al.,
2006). The major action spectrum for inducing sunburn cells is within the UVB
range (290-320nm), they can also be found after irradiation with UVC (200-290nm)
or high dose UVA (320-400nm). Sunburn cells are detectable from 8 hours after
irradiation, maximal 24-48 hours and disappear by 60-72 hours(Kulms and Schwarz,
2000).
The three most important mechanisms for the induction of apoptosis are(Murphy et
al., 2001):
• DNA photodamage, involving p53 induction - the two main lesions resulting
from photochemical reactions within DNA are cyclobutane pyrimidine
dimers (CPDs) and 6-4 photoproducts (6-4PPs), these are collectively termed
DNA photoproducts. p53 causes cell cycle G1 arrest and regulation of
transcription and cell differentiation. p53 dependent post-UVR arrest of cells
in G1 allows DNA repair prior to DNA synthesis, this reduces DNA
photoproducts and the need for apoptosis.
• Death receptor activation or release of their ligands - cell surface death
receptors induce apoptosis on activation. The TNF death receptor superfamily
includes: TNF-receptor-1, CD95 (Fas/Apo-1), TRAIL-receptorsl and 2, and
death receptor-3 (DR3). UVA, B and C have all been shown to induce CD95
expression. Although DNA is the major molecular target for UVB,
membrane/cytoplasmic targets, such as death receptors, are also relevant.
• Oxidative stress activates mitochondrial pathways and cytochrome C release
- cytochrome C release seems to be an early and critical event in UVR-driven
apoptosis. Apoptosis is normally finely regulated by pro- and anti-apoptotic
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proteins. Anti-apoptotic proteins stabilise the transmembrane potential of
mitochondrial membranes. UVR can initiate cell death by inducing
'megapore' formation in the mitochondrial membrane, this results in
cytochrome C release into the cytoplasm which activates caspase 9 and
thereafter apoptosis.
The terminal events in all apoptotic pathways include the activiation of a series of
cytoplasmic proteases termed caspases.
Apoptosis combines a unique series of events, this was initially based on recognition
ofmorphological changes in cell structures during apoptosis. Apoptosis is a highly
conserved mechanism that shows uniformity through evolution, this allows
extrapolation between species, systems, cell culture and intact tissue. The surface
morphological features of apoptotic cells in culture include, blebs, echinoid spikes
and surface blisters(Collins et al., 1997b) (figure 1.11).




Different events within the apoptosis process have been targeted in order to detect
apoptotic cells in individual cells, mass cell cultures and intact tissues. The main
categories of cellular changes that form the basis of apoptotic assays are seen below
(subheadings highlight those methods that are appropriate for use in intact tissues,
i.e. as in our studies):
• Changes in surface morphology and composition
o Morphological changes evident on H&E (eg sunburn cells)
• Nuclear events and DNA cleavage
o Segmentation of chromatin and nuclei
o DNA cleavage in situ; detection of strand breaks
■ In situ nick-translation (ISNT)
■ Terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labelling (TUNEL)
■ Anti-single-stranded DNA antibody
• Cell dissolution
• Cytoplasmic biochemical activation events
o Caspase cleavage products
o Caspase activity
• Mitochondrial function and integrity
During experimental design it is important to remember that apoptosis is not a
synchronous event. Cells within a population may begin cell death at different times,
and the lengths of the various stages of apoptotic morphological change can vary
from cell to cell(Collins et al., 1997a). Some assays detect changes that occur early in
the process whereas others detect changes that occur very late. In addition not all
methods of detection are suitable for all cells undergoing apoptosis, for example
Annexin V binding (a marker of phospholipid externalisation) has been shown only
to occur in 30% of the cells undergoing apoptosis(Willingham, 1999). The
asynchronicity of apoptosis, combined with the variability between different
detection methods, dictates that when designing experiments to quantify apoptosis at
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least two, if not three, different methods of detection should be employed. The most
specific assay is probably the oldest, the detection of nuclear shape changes in early
apoptosis.
1.6.2.4.DNA damage/repair
The type ofDNA damage induced by UVR depends on the wavelength of the
photons that hit the cell. UVB exposure results in direct light absorption by DNA,
this induces dimerisation reactions between adjacent pyrimidine bases and the
formation of DNA photoproducts (PPs). DNA PPs are characterised by C to T or CC
to TT transitions. The transitions are regarded as 'signature' mutations, their
presence is very suggestive ofUY being the cause(Brash et al., 1991). Cyclobutane
pyrimidine dimers in general and thymine dimers in particular, are the major DNA
PPs. The remainder of PPs are accounted for by 6-4PPs. 6-4 photoproducts may be
converted into their Dewar isomers upon exposure to near UVR (figure 1.12).
Figure 1.12 DNA photoproducts
UVB only contributes to 5% ofUVR reaching the earth's surface, but it induces the
majority ofDNA damage due to the strong absorption ofDNA at UVB
wavelengths(Douki et al., 2003). However, all UVR wavelengths have been shown
to induce DNA PPs(Douki et al., 2003;Kobayashi et al., 2001 ;Mouret et al.,
2006;Sheehan et al., 2002).
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The formation of 6-4PPs induces greater distortion in the DNA back bone than
CPDs, this is thought to result in the comparably faster DNA repair of 6-4PPs that
has been observed(Young et al., 1996). The actual rate of repair ofUV induced DNA
damage is widely debated and published figures for a t\n of repair ofCPD PPs
ranges from 40-50% removal within 1 hour(D'Ambrosio et al., 1981;Reusch et al.,
1988) to a ti/2 of 33.3 hours(Young et al., 1996), with one group suggesting that
almost complete removal ofCPDs can take up to 72 hours after exposure to as little
as 1.2MED(de Winter et al., 2001).
1.6.2.5.p53
Critical proteins involved in the response to DNA damage include the p53 tumour
suppressor protein. p53 is an important transcriptional factor and also directly reacts
with proteins such as nucleotide excision repair (NER)-associated regulatory
proteins. Upon activation of p53, cells have two possible outcomes(Chow and Tron,
2005):
• Cell cycle arrest with DNA repair
• Apoptosis
Evidence for the involvement of PPs in skin carcinogenesis is provided by the
finding of C to T and CC to TT tandem mutations in p53 tumour suppressor genes
isolated from skin tumours(Brash et al., 1991;Brash et al., 1996;Dumaz et al.,
1993;Ziegler et al., 1993). Mutated p53 is unable to induce apoptosis, therefore
allowing for the persistence ofDNA damaged cells and mutagenesis.
1.6.2.6.Non melanoma skin cancer
Two mechanisms have been proposed to explain the development of non melanoma
skin cancer (NMSC):




• UVR-induced immunosuppression(Nishigori et al., 1996), which may be
mediated by CPDs(Kripke et al., 1992).
The finding ofCC to TT tandem mutations in the p53 gene of basal cell carcinomas
and squamous cell carcinomas provide evidence of a relationship between UV-
induced DNA PPs andNMSC in man(Nakazawa et al., 1994). Xeroderma
pigmentosum (XP) patients have an incidence ofNMSC which is 1000 fold greater
than that seen in normal subjects. XP patients exhibit a deficiency in their ability to
repair damaged DNA, this lack of repair ofDNA PPs in XP patients further indicates
an association between DNA photodamage and human NMSC(Nakazawa et al.,
1994;Dumaz et al., 1993;Ziegler et al., 1993).
1.6.3. UVR and NO
1.6.3.1. UVR andNO stores
The first evidence that NO-related products exibit photoproperties was provided by
Furchgott et al. in 1955, he demonstrated that light had a relaxant effect on vascular
smooth muscle(Furchgott et al., 1955).The action spectra for the photorelaxation in
rabbit aorta peaked at 310nm with a shoulder at 350nm, following incubation with
N02~ 355nm dominated the action spectrum(Furchgott et al., 1961). More recently
Rodriguez J et al., have further investigated the photochemical properties of NO
related substances (table 1.2), using biochemical and optical approaches, they show
that the amounts ofN02" and RSNOs fully account for the photorelaxation observed
in rat aortic tissue. A strikingly close match was observed in the amplitudes of the
action spectra for NO release and those of the action spectra for photorelaxation.
RSNOs have the highest photoactivity, followed by RNNOs, and N02"; NO3"
photoactivity is negligible. Consistency between biochemical, photolytical and
functional results indicate the presence of two NO stores that dominated the action
spectra for photorelaxation: a GSNO-like substance (RSNOs) and N02". Megson et
al., also demonstrate photorelaxation with a GSNO-like substance in v/vo(Megson et
al., 2000). Nitrite probably contributes most highly to enzyme-independent
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photorelaxation in vivo as it is present in the highest concentration compared with the
more photoactive RSNOs(Rodriguez et al., 2003).






Table 1.2 Photochemicalproperties ofNO-relatedproducts(\{o&r\g\iez et al., 2003)
The photolytic properties ofNO-related products have been utilised to quantify the
RSNOs(Rodriguez et al., 2003;Stamler et al., 1992b;Stamler et al., 1992a;Tyurin et
al., 2001) and N02~ content ofmedia(Rodriguez et al., 2003). Two independent
groups have demonstrated a non-linear behaviour of the RSNO/NO pathway, in thiol
containing samples photolysis of both NO3" and NO2" is catalysed by the presence of
thiols(Paunel et al., 2005;Dejam et al., 2003). This will undoubtedly have
implications for those groups that advocate the use ofphotolysis in the quantification
ofNO metabolites in biological samples.
Using ex vivo skin biopsy specimens, UVA irradiation has been shown to induce
photolysis ofRSNO and N02~ stored in human skin with subsequent high-output
enzyme-independent NO formation. This reaches a maximum 20 minutes after the
onset of irradiation(Paunel et al., 2005) (figure 1.13). It has been postulated that this
rapid enzyme-independent release ofNO post UVR is biologically important and




UVR, predominantly UVB and in some subjects UVA, induces upregulation of iNOS
expression in human epidermis. UVR-induced iNOS expression starts 8-10 hours
after UVR and is maximal at 24 hours, maximal activity thus corresponds with UVR-
induced erythema (figure 1.13). Epidermal iNOS expression returns to baseline three




Figure 1.13 UVR-induced enzyme-independent and dependent NO release
1.6.3.3. UVR-induced erythema and NO
UVB, the major erythemogenic wavelength ofUVR, induces the release ofmany
mediators including NO(Warren, 1994;Goldsmith et ah, 1996). It has been shown
that UVR-induced erythema is significantly reduced by inhibitors ofNOS(Goldsmith
et ah, 1996). These findings make the quantification of erythema a useful biological
measure of NO production.
1.6.3.4. UVR-induced apoptosis andNO
The pleiotropic nature of NO is exemplified when considering its role in cell
apoptosis and DNA damage. NO has been shown to exert cytotoxic effects and
initiate the onset of apoptosis in mammalian cells(Kroncke et ah, 1997), however it
has also been shown to protect against the detrimental actions of superoxide,
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hydrogen peroxide and alkyl peroxides(Wink et al., 1996b). NO-induced DNA
alterations may lead to p53 post-translational modifications, accumulation and
activation(Forrester et al., 1996;Messmer and Brune, 1996;Nakaya et al., 2000), thus
contributing to the anti-carcinogenic effects ofp53. In addition, NO may modulate
tumour DNA repair mechanisms by up-regulating poly (ADP-ribose) polymerase
(PARP) and the DNA-dependent protein kinase (DNA-PK)(Xu et al., 2002). In
contrast, high levels ofNO have been shown to mutate the p53 gene allowing for
selective clonal expansion of p53-mutant cells, and tumorigenesis(Greenblatt et al.,
1994).
Recent evidence suggests that NO has an anti-apoptotic role in skin after exposure to
UVR. iNOS derived NO has been shown to protect rat endothelial cells in vitro
against UVA-induced apoptosis(Suschek et al., 1999). Enzyme independent
mechanisms are also important, the presence ofNO2" in vitro has been shown to
protect endothelial cells from UVA induced apoptosis, in a concentration-dependent
manner. It is postulated that NO2" forms NO which acts anti-apoptotically(Suschek et
al., 2003b). An anti-apoptotic role for NO has also been demonstrated in human
keratinocytes in vitro and murine keratinocytes in vivo following UVB
exposure(Weller et al., 2003). The emerging evidence suggesting an anti-apoptotic
role for NO in human keratinocytes following UV exposure, has led to the
hypothesis that the rapid enzyme-independent release ofNO post UVR is
biologically important and potentially 'bridges the gap' between UV challenge and
the enzymatic up-regulation and activity of iNOS(Paunel et al., 2005).
1.7. NO donors
The ubiquity of the biological actions ofNO offers many promising pharmacologic
benefits, however it is at the same time its downfall. The two major practical
problems when considering NO as a therapeutic modality are the lack of specificity,
which may result in unwanted side effects, and the lack of adequate
pharmacokinetically appropriate and localised means ofNO delivery.
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1.7.1. General NO donor drugs
NO gas is notoriously difficult to handle on account of the problems associated with
complete exclusion of oxygen to prevent oxidation to NO2. NO donors offer the
property of stabilising the radical until its release is required. A number of different
classes ofNO donor drugs already exist, these are categorised by the species derived
and the metabolic process underlying NO release(Megson and Webb, 2002).
• The organic nitrates are the most commonly used NO donor drugs in the
clinical setting. These include glyceryl trinitrate (GTN) and isosorbide
mononitrate (ISMN), they are used for the acute and chronic treatment of
angina respectively.
• Sodium nitroprusside (SNP), azide and hydroxylamine require complex
metabolism to generate intracellular NO. Release ofNO from azide and
hydroxylamine is catalase-dependent, while membrane bound proteins are
thought to have a role in NO generation from SNP.
• S-nitrosothiols cover a vast array of different compounds which contain a
single chemical bond between a SH-group and the NO moiety. Biological
activity ofRSNOs is highly influenced by the molecular environment of the
parent thiol. They can release NO spontaneously, and also have the ability to
transfer NO to free reduced thiols and cysteine residues in proteins, thus
modulating enzyme activity, this may constitute an important component of
their cellular effects(Butler and Rhodes, 1997).
• Diazeniumdiolate, or 'NONOate', compounds are nucleophiles with two
molecules ofNO, which are spontaneously released in aqueous solution in a
temperature and pH-dependent reaction. A wide variety of diazeniumdiolates
are available, such as SPER/NO, DEA/NO and diethylenetriamine
(DETA/NO) - based compounds, each with a different rate of release ofNO
that depends on the nature of the nucleophile(Hrabie et al., 1993).
• The syndonimines are frequently used in studies into the effects ofNO. These
compounds generate equal amounts ofNO and O2", which combine rapidly to
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form ONOO"; as a result they are generally considered to be ONOO" donors
(Feelisch et al., 1989).
• A novel approach to storage and delivery ofNO has recently been adopted
using ion-exchanged zeolites (Ze)(Wheatley et al., 2006). These are
microporous insoluble materials that form a framework containing metal ions
that can bind NO. Zeolite-NO (Ze-NO) produces effects caused directly by
NO itself. Ze based compounds are already used clinically as MRI
gastrointestinal contrast agents and as clotting enhancers.
1.7.1.1. Cutaneous NO donor drugs
In general the enormous variety of effects ofNO in different tissues and systems
might be a considerable limitation to systemic NO delivery, with unwanted side
effects outside the target tissue. An advantage of studying the effects ofNO on
human skin is that many of these problems are avoided, as topical application ofNO
donors should theoretically reduce systemic side effects, while still delivering
relevant concentrations ofNO to produce a clinical effect. The synthesis of topical
NO donors for use on the skin has been a more recent development, these include
donors based on:
• The chemical reduction ofNO2" such as acidified N02"(Ormerod et al.,
1999a).
• The spontaneous release by nitroso-sugars(Khan et al., 2003).
• The spontaneous release by diazeniumdiolates(Masters et al., 2002).
• The spontaneous release by RSNOs in a hydrogel(Seabra et al., 2004).
• Release by poly-S-nitrosated polyesters(Seabra et al., 2005).
• Release from iontophoresed iron nitrosyl complexes(Jagren et al.,
2002;Webster and Mahajan, 2002).
• Release from a Ze framework ofmetal ions that can bind NO.
1.7.1.2.Zeolites as NO donor drugs
Zeolites are a class of highly crystalline aluminosilicate microporous materials.
They have an inorganic, infinitely extending rigid three-dimensional network of
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channels, cages and rings, composed of fully linked, comer-sharing tetrahedra built
from an open network composed ofAIO4 and Si04. The open structure of the
framework allows ion exchange, reversible dehydration and the adsorption of small
molecules such as NO. Zeolites are used extensively in washing powder formulations
as water softeners, sodium-calcium exchange takes place within the zeolite structure.
Zeolites can be used to store gaseous NO, which is released on hydration (as after
application to the skin). The kinetics ofNO release can be adjusted by varying the
structure, metal ion content and vehicle containing the Ze(Wheatley et al., 2006;Xiao
et al., 2007). Zeolite-A (LTA) consists of alternating Si04and AIO4 tetrahedra that
share comers to produce an open framework. It has a natural affinity for NO which
is bound within the framework, and NO is released (delivered) from this stable
storage material in biologically relevant amounts on contact with water. Ze-NO has
anti-thrombotic properties, by inhibiting platelet aggregation and adhesion in
plasma(Wheatley et al., 2006). The release kinetics ofNO from Ze can be tailored
by altering the type and number ofmetal cations in the structure, allowing NO
delivery patterns to be modulated to specific clinical requirements. Colleagues in the
School ofChemistry, University of St Andrews have recently developed an effective
topical NO donor based on Ze.
#AI/Si
HO




Historically inorganic nitrogen oxides have a long and rich history, however recent
advances in the field ofNO have only been made since the 1980s. NO plays a major
role in human skin, in particular in the context of photobiology. Following UV
exposure NO stores present in human skin release NO by enzyme-independent
photolysis within 20 minutes ofUV exposure. Enzyme-dependent NO release begins
8-10 hours after UV exposure and is maximal by 24 hours. Data from human
keratinocytes in vitro and murine keratinocytes in vivo suggest that NO is having an
anti-apoptotic role in human skin following UVR(Weller et al., 2003). NO is
biologically active in many systems, however it has pleiotropic actions depending
upon its concentration, target organ and microenvironment. The divergent nature of
NO make it imperative to direct research towards in vivo clinical studies, in order to




1.9.1. NO donors and inflammation
• To elucidate the inflammatory properties ofNO




• To investigate the suggested inert properties ofZe-NO as an NO donor, and
therefore the use ofZe-NO for manipulation of the NO environment in future
studies.
1.9.2. NO stores in human skin
• To quantify NO-related products in human skin in vivo:
o In sweat on the skin surface
o In epidermis
o In superficial vascular dermis
• To determine in vivo the extent to which NO release can be demonstrated
during UVA irradiation.
1.9.3. NO and UVR-induced apoptosis, p53 & DNA damage/repair
• To determine the influence ofphysiologically relevant concentrations of
UVR in the presence/absence of exogenous NO on:
o Apoptosis
o p53 accumulation
o DNA damage and repair
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1.9.4. NO, UVB and arginase in human skin
• To further investigate preliminary findings which suggest a feedback control







2. CHAPTER 2 - METHODS
Chapter 2
This chapter includes all methods which are common to more than one experiment.
All other methods are included within the methods section of the individual chapters.
2.1. Study volunteers
All the studies used healthy volunteer subjects. All subjects had Fitzpatrick skin type
I or II, except for the NO/UVB-induced upregulation ofarginase study in which one
subject had skin type IV. None of the subjects were using either topical or systemic
medications at the time of the study. The Lothian Regional Ethics Committee
approved all the studies and all volunteers gave written informed consent. All the
studies were conducted according to the principles of the declaration ofHelsinki.
2.2. Preparation and application oftopical NO donors
Zeolite manganese NO (Ze-NO) was used as a NO donor in all studies. This is an
inert topical formulation which releases NO on mixing Ze-NO powder with an
aqueous vehicle(Mowbray et al., 2008). Immediately before application Ze-NO
powder was mixed with aqueous cream BP® and applied to the skin surface.
Aqueous cream BP® was used as a vehicle control in all experiments. All topical
preparations were occluded with Tegaderm™ after each application. Ze-NO donor
was mixed at a concentration of 33% wt/wt for all experiments. A 33% wt/wt
formulation comprises the maximum ratio ofZe-NO powder to aqueous cream,
while maintaining the ability to apply the formulation to the skin surface.
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a) Epidermis b) Full thickness epidermis and dermis
Figure 2.1 a & b Sites ofhuman skin sampling using different methods
2.3.1. Epidermal tape stripping
D-Squame" (CuDerm Corp., Dallas, TX, USA) strips, diameter 22mm, surface area
3.8cm2, were used to sample the stratum corneum (superficial epidermis, figure
2. la). Strips were placed on the skin and the skin marked to ensure sampling from
the same site. Equal pressure was applied to each strip by pressing with a spring
loaded stamp for two seconds duration, strips were then removed with tweezers and
stored on a cellophane sheet at -70 C until further analysis (figure 2.2).
Figure 2.2 Epidermal tape strip materials and method
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2.3.2. Epidermal suction blister and fluid, harvest and homogensation
Up to ten epidermal suction blisters were formed on the volar forearm of each
volunteer using two suction blister cups (dermovac®, Ventipress Oy, Lappeenranta,
Finland). Each cup creates five 5mm diameter blisters, the split occurs at the dermo-
epidermal junction (figure 2.1a & b, figure 2.3). Epidermal suction blister fluid was
removed using a sterile 1ml insulin syringe (BD PlastipakTM), the blister cavity was
then filled with Xylocaine® 1% with adrenaline (epinephrine) 1:200.000 (Astra
Zeneca LTD.,Luton, UK). The blister roof was harvested aseptically using fine
scissors. Epidermal suction blister samples were placed immediately into ceramic
bead beating tubes (CK-14, Stretton scientific Ltd., Stretton, UK) containing
NEM/EDTA/trypsin. Epidermal suction blisterfluid was placed immediately into
eppendorfs containing NEM/EDTA. A Precellys 24 homogeniser (SS-Bertin-01,
Stretton scientific Ltd., Stretton, UK) was used to homogenise the epidermal suction
blister samples, two cycles with a three minute break (on ice) at 5,500
revolutions/minute (a cycle consists of three 20 second active periods with 30seconds
rest between each). Post-homogenisation, samples were centrifuged and supernatant
transferred into eppendorfs for storage prior to quantification of NO-related products.
Figure 2.3 Epidermal suction blister and blister cup
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In all experiments where full thickness skin biopsies were taken a 4mm diameter
sterile disposable punch biopsy was used (StiefelH Laboratories, Bucks, UK). Skin
was anaethetised with an intradermal injection of 1% lignocaine with adrenaline
prior to biopsies being taken. Biopsy wounds were closed using 4/0 ethilon sutures
(Ethicon, Johnson and Johnson medical Ltd., W Lothian, UK). All 4mm full
thickness skin punch biopsies were fixed in 4% buffered formaldehyde prior to
processing for histology.
2.3.4. Cutaneous microdialysis sampling of superficial vascular dermis
Dermal microdialysis catheters were made by the technique of Clough(Clough et al.,
1998) and sterilized by ethylene-oxidisation. Sites on the volar aspect of the forearm
and the tlexor aspect of the upper arm were used for catheter insertion. Prior to
catheter insertion sites were anaesthetized with topical 5% EMLA" cream, applied
for 1 hour. Using the Seldinger technique and a 23-gauge needle (BD Microlance™
0.6mm x 2 5mm, Consumer Healthcare, Franklin Lakes, New Jersey), microdialysis
catheters were inserted into the superficial dermis parallel with the skin surface
(figure 2.1 b & 2.4). Either normal saline or Noradrenaline (1:1,000 Abbott
laboratories Ltd Kent, UK) was dialysed continuously through the catheters at a rate
of 2pL/min, using 1ml Micro-Fine™ insulin syringes (BD Consumer Healthcare,
Franklin Lakes, New Jersey) and a microinfusion pump (PHD 2000 infusion pump,
Harvard Apparatus, Holliston, M.A.). Noradrenaline was diluted 1:80 with normal
saline. Dialysate was collected continuously in 15 minute aliquots throughout each
experiment. Following insertion of the microdialysis catheters dialysate was




Figure 2.4 Cutaneous microdialysis, a method ofsamplingfrom superficial vascular dermis
2.4. Determination of the protein concentration ofbiological samples
When necessary protein concentrations of biological samples in solution were
determined using a colourimetric Bradford protein assay (Bradford reagent, Bio-Rad
Labs., Hercules, CA) in a microtiter plate format (Tekin S, Dept Animal Sciences,
University of florida). Samples were analysed in triplicate at dilutions of: 1:60, 1:80
and 1:100.
2.5. Chemiluminescence Assayfor nitrate, nitrite and ISO-relatedproducts in
biological samples
Total NO-related products and individual concentrations of NO.T, NO:", RSNOs and
RNNOs were quantified in solutions of various biological samples. All samples
were frozen at -70°C immediately after collection, and analysed within three days.
Cutaneous microdialysis samples were analysed within 24 hours of collection for
total NO-related products only, due to the small sample volume. Unless otherwise
indicated samples were kept on ice in the dark during processing. Epidermal suction
blisters were stored in N-ethylmaleimide (NEM)/ethylenediamine tetra acetic acid
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(EDTA)/trypsin prior to analysis (final concentration 5mM/2mM/xl). Suction blister
fluid, sweat, blood and saliva samples were stored in NEM/EDTA (final
concentration 5mM/2mM). NEM alkylates free thiols and stabilises RSNOs
preventing any further S-nitrosation(Marley et al., 2000). EDTA forms inert
complexes with transition metals, several of which can accelerate RSNO degradation
even at low concentration(Mcaninly et al., 1993).
NO3", NOi", RSNO and RNNO concentrations were determined by reductive
denitrosation with an iodide/triiodide containing reducing mixture and subsequent
measurement of the gaseous NO released by its chemiluminescent reaction with O3,
as described by Feelisch et a/.(Feelisch et al., 2002;Marley et al., 2000) (figure 1.7).
Samples (volume 10-100pl) were introduced using a gastight syringe (SGE
International Pty Ltd, Ringwood, Australia) into a sealed reaction vessel containing
the reducing mixture of 45mmol/l potassium iodide (KI) and 10mmol/l iodine (E) in
glacial acetic acid. A constant flow of nitrogen gas was bubbled through the reaction
vessel which was maintained at a temperature of 60°C in a thermostatically
controlled water bath (Grant Instruments (Cambridge) Ltd, England). The effluent
gas was passed through a scrubbing bottle containing sodium hydroxide (1 mol/L;
0°C) to trap traces of acid and iodine before transfer into the chemiluminescence
meter (42C NO-NCL-NOx Analyser, Thermo Environmental Instruments Inc,
Franklin, Massachusetts). The chemiluminescence meter was connected to an
analogue-digital signal converter (PowerLab® 2/25 ADInstruments, Castle Hill,
NSW, Australia) and the output processed by PowerLab"' System Chart & Scope for
Windows* (v5.1.1, AD Instruments).
Without having to change reduction mixture or conditions, NOf, NO2", RSNOs and
RNNOs can be differentiated by pre-treatment with group specific reagents before
analysis according to the technique of Feelisch et a/.(Feelisch et al., 2002) (chapter
1.5.3.1, figure 1.8). All individual NO-related products were quantified in terms of




NO2" measurements were made by dividing samples into two aliquots. Direct
injection of one aliquot into the tri-iodide reducing mixture measured NO derived
from NO2", RSNO and RNNO. Sulfanilamide reacts specifically with nitrite to form
a stable diazonium ion which is unaffected by the reducing mixture. The second
aliquot was pretreated with 10% (v/v) of a 5% solution of sulphanilamide in IN HC1
(final concentration 29mmol/L) and incubated for 15 minutes at room temperature
(RT). Subtracting pre-treated aliquot derived NO from the untreated aliquot derived
NO gave the amount ofN02".
2.5.2. RSNO assay
Incubation with HgCL results in cleavage of the S-NO bond (Saville reaction)
(Feelisch et al., 2002) without affecting peak shape or recovery of NO2" or NO.
RSNO concentration in each sample was quantified by subtraction of the peak area
of sample aliquots pretreated with a solution of sulfanilamide and mercuric chloride
at RT for 30 minutes (10% (v/v) of 5% sulphanilamide + 0.2% HgCf in IN HC1
(final concentration 7.3mmol/L)) from that of sample aliquots just treated with
sulphanilamide at RT for 15 minutes (10% (v/v) of 5% sulphanilamide in IN HC1).
2.5.3. RNNO or metal nitrosyls assay
The peak remaining after preincubation with HgCb/sulphanilamide/H^ represents the
presence of RNNOs or metal nitrosyls in the sample.
2.5.4. Nitrate assay
NO3" was reduced to NO2" by enzymatic reduction(Schmidt.H and Kelm.M, 1996). A
1:30 mix of NO3" reductase solutiombiological sample was incubated at 37°C for 15
minutes. The NO3" reductase solution was premixed using Aspergillus purified NO3
reductase (final concentration O.lU/ml) (SIGMA-ALDRICH, Germany), flavine
adenine dinucleotide (FAD, final concentration 5pM) (SIGMA-ALDRICH,
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Germany) and reduced P-nicotinamide dinucleotide phosphate (NADPH, final
concentration 0.03mM) (S1GMA-ALDRICH, Germany) in double distilled water.
The amount of NO3" was quantified by subtracting the peak area of the untreated
aliquot from that of the aliquot pre-treated with NO3" reductase solution.
Prior to the analysis of each batch of biological samples, a range of NO?" standards
(Sodium NO2", AnalR, BDH Chemicals Ltd, UK) were injected into the reaction
vessel in order to calibrate the gaseous NO released as equivalent NO/
concentration. Assay reproducibility was determined by comparison of the peak area
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Figure 2.5 Powerlab tracing ofchemiluminescent analysis ofnitrite standards analysed in triplicate
Nitrite standards were analysed at the beginning and end of each set of biological





Figure 2.6 Reproducibility ofnitrite standards analysed before and after a set ofbiological solutions
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Analysis revealed a small amount of degradation in NCV standards over time,
therefore NO2" standards were replaced every two weeks and new standards
compared with the old before discarding the latter.
—a—week 1
—b—week 4
0 2E-06 4E-06 6E-06 8E-06 0.00001 1.2E-05
Nitrite mM
Figure 2.7 Degredation ofnitrite standards over a four weekperiod
All gastight syringes were washed out with acetone between sample batch analysis to
minimise NCVand organic contaminants. Control solutions ofNEM/EDTA were
analysed for contamination with NO-related products where appropriate.
Many laboratory materials have the potential for contamination with minute
quantities ofN02" which may affect results. All vehicle solutions were analysed to
ensure that there was no NO2" contamination which would influence the results. It is
not possible to ensure zero measurements ofNCV within such laboratory solutions,
as the method of gas-phase chemiluminescence is so sensitive. Minimal
contamination of laboratory solutions was observed, as can be seen by comparison
























Figure 2.8 Nitrite concentration measured in laboratory/vehicle solutions
2.6. Determination ofminimal erythemal dose (MED)
For all studies requiring assessment of the MED prior to commencement of the
study, subjects attended on day one where they received five graded doses ofUVB to
five individual areas on the volar aspect of the dominant forearm, each measuring 1 x
2cm . The MED range used was matched to body site and skin type using a
departmental protocol(Waterston et al., 2004). Subjects returned 24 hours later to
have their MED read, a subjects MED was defined as the minimal dose producing
uniform erythema with clearly defined template margins.
2.7. Statistical analysis
Data for individual subjects are presented as means of duplicate or triplicate samples.
Pooled data is presented as means ± standard error of the mean (SEM) and
differences judged as significant if the p-value was lower than 0.05, as determined by
the paired two tailed Student's t-test. Analysis of variance (ANOVA) was used to
determine significant differences between three or more observations. ANOVA tests
the hypothesis that means from two or more samples are equal. Box plots showing
the median and inter-quartile range (IQR) with points representing maximum,
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minimum and mean values are used to display inter individual variation.
Relationships between an independent variable (eg plasma NO-related products) and
a dependent variable (eg sweat or superficial dermal NO-related products) are shown
by regression analysis. The proportion of variation is displayed by the (correlation
coefficient)2 (R2). Data analyses were conducted using Microsoft® Excel Software,
v5 and MINITAB® release 14 for windows.
2.8. Selecting a method oftissue homogenisation
All biological samples to be analysed for gas-phase chemiluminescence
quantification of individual NO-related products are required to be in the form of a
solution. Various methods of homogenisation were trialed prior to selecting the most
effective method. Both full thickness skin biopsies and in particular epidermal
suction blisters pose a challenge for homogenisation. The main problem in achieving
adequate homogenisation lies in the elastic nature of the tissue. Methods which were
compared for their effectiveness at fully homogenising tissue include (with and
without prior trypsinisation):
• Sonicator
• Tissue tearor (mini liquidizer)
• Precellys 24 (glass bead whirlimixer)
A number of factors are important to bear in mind when selecting the most
appropriate method of homogenisation. All samples are being prepared for
quantification of individual NO-related products. In order to ensure that results
accurately demonstrate the in vivo distribution ofNO-related products, samples
should be kept in the dark and below 4°C at all times, this ensures maximum stability
of the individual NO-related products and an accurate representation of their in vivo
state. More obvious requirements include selection of the method that provides the




2.8.1. Homogenisation using a sonicator
This was the first method of homogenisation to be trialed. Sonicator homogenisation
utilizes focused high frequency acoustic waves to create a powerful vortex. This
process was performed in a dark room, samples were stored on ice between cycles.
Unfortunately this did not prove to be a useful method for a number of reasons:
• Samples required multiple cycles of treatment to achieve maximal
homogenisation (3x3 second pulses repeated 6 times —> 30 minute rest on
ice —> 3 x 3 second pulses repeated 6 times). Each cycle of treatment resulted
in heating of the biological sample, despite introducing a long rest period on
ice. Such heating will potentially destabilise individual NO-related products.
• This method results in frothing of the biological sample which led to
occasional loss of tissue.
• Despite maximizing the effectiveness of the homogenisation process as best
as possible, there remained high variability in effectiveness of
homogenisation between samples. This variability could be observed visually
simply by inspecting the sizes of tissue specimens suspended within the
sample solutions.
2.8.2. Homogenisation using a tissue tearor
The tissue tearor (Biospec products,Inc., Oklahoma) is a rotor/stator type tissue
homogeniser which rapidly homogenises, disperses, and emulsifies samples in 0.5 -
50 ml of liquid. The rotor turns at 5-30,000 rpm. Although not ideal, use of the tissue
tearor with prior trypsinisation of samples for 1 hour proved more reliable than
homogenisation using the sonicator. Some problems still remain with the use of the
tissue tearor for homogenisation, these include:
• Occasional loss of tissue from the eppendorf.
• Tissue can get stuck between the rotating blade and the protective outer
casing without being homogenised.
• This method requires repetitive cycles at the highest speed, on ice, resulting
in a duration ofprocessing for 10 suction blister samples of 2 hours. The time
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taken to process individual samples increases the potential of exposure to
variations in temperature/light which may destabilise NO-related products.
• Variability in the effectiveness of homogenisation was again observed, some
samples of tissue remained visibly larger than others.
2.8.3. Homogenisation using the Precellys 24
Precellys 24(SS-Bertin-01, Stretton scientific Ltd., Stretton, UK). Biological samples
are introduced into sterile ceramic bead beating tubes. High speed whirlimixing in a
'figure of eight motion' results in the rapid, uniform homogenisation of skin tissue
samples. The final biological solution is homogenous and milky-white, no residual
tissue fragments are visible. Twenty-four samples can be processed at any one time.
The effective homogenisation of skin tissue requires two cycles with a 3 minute
break between each (on ice) at 5,500 revolutions/minute (a cycle consists of three 20
second active periods with 30 seconds rest between each). Homogenisation using the
Precellys 24 tissue homogenizer was chosen as the desired method of tissue
homogenisation for a number of reasons:
• Rapid processing of a number of samples at one time, thus minimising
exposure to both heat and light.
• No loss of biological tissue.
• Less variability of homogenisation between samples in comparison with
other methods trialed, demonstrated both by visual inspection and by













Figure 2.9 Comparison ofhomogenisation using Tissue tearor and Precellys 24
Tissue tearor mean 0.21±0.16mg/mlprotein, SEM0.06










3. CHAPTER 3 - NO DONORS AND INFLAMMATION
3.1. Introduction
NO is well known for its divergent effects, in particular in the processes of apoptosis
and inflammation. The effects ofNO are dependent on a number of factors,
including: the source ofNO, the redox form and pH of the microenvironment, and
the target cells in tissue. The pleiotropic actions ofNO are exemplified when
studying the role it plays in inflammation.
NO has many anti-inflammatory properties:
• NO diminishes endothelial permeability(Granger and Kubes, 1996).
• NO donors reduce oedema formation in various experimental models(Hinder
et al., 1999).
• NOS inhibitors can exacerbate oedema formation(Mundy and Dorrington,
2000).
• Leukocyte and platelet adherence to the endothelium are inhibited by
NO(Clancy et al., 1992;Kubes etal., 1991).
• The production of superoxide anions by leukocytes is inhibited by
NO(Clancy etal, 1992).
• NO inhibits macrophage degranulation(Clancy and Abramson, 2000).
Evidence also exists of pro-inflammatory properties ofNO:
• In experimental models of inflammation NO has been shown to promote
carrageenin-induced oedema in the mouse footpad(Ianaro et al., 1994).
• NO induces vasodilation in the neurogenic inflammatory reaction of the rat
hindpaw skin to topical application of mustard oil(Lippe et al., 1993).
• Inducible NOS protein has been demonstrated immunohistochemically in
many inflammatory diseases including a number of different inflammatory
dermatoses: psoriasis(Kolb-Bachofen et al., 1994;Sakai et al., 1996), atopic
dermatitis(Clancy et al., 1998;Rowe et al., 1997) and LE(Clancy et al., 1998).
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Subsequent to the isolation of iNOS in psoriasis, contact dermatitis and atopic
dermatitis, Ormerod et al. studied the effects of topical acidified NO2" on the
skin(Ormerod et al., 1999a). This NO donor was made by mixing ascorbate and NO2"
at concentrations of either 0.5% or 5% with a vehicle control of aqueous
cream(Ormerod et al., 1999a). An intense inflammatory infiltrate with CD3, CD4,
CD8, CD68 and neutrophil elastase expressing cells was seen at sites of acidified
NO2" application, this set the paradigm that NO is a pro-inflammatory mediator in
human skin.
Synthesis of topical NO donors for use on the skin is a recent development. An
important feature of such donors is the inert nature of the carrier molecule or vehicle.
Zeolites are a class of highly crystalline aluminosilicate microporous materials.
They have an inorganic, infinitely extending rigid three-dimensional network of
channels, cages and rings, composed of fully linked, comer-sharing tetrahedra built
from an open network composed of AIO4 and Si04. The open structure of the
framework allows ion exchange, reversible dehydration and the adsorption of small
molecules such as NO. Zeolites are used extensively in washing powder formulations
as water softeners and are generally regarded as being inert. We have used Zeolites
to store gaseous NO, which is released on hydration (as after application to the skin).
The kinetics ofNO release can be adjusted by varying the structure, metal ion
content and vehicle containing the Ze(Wheatley et al., 2006;Xiao et al., 2007). Dr
Weller's research group has experience with the topical NO donors acidified NO2'
(Weller et al., 1998), RSNOs(Seabra et al., 2004) and Ze-NO, and have observed
little clinical inflammation following RSNO and Ze-NO application. This suggests
that NO itself is not as potent a pro-inflammatory mediator as the early data shows,
but that the release of species other than NO might have accounted for the
inflammatory effects of acidified NO2".
Since the first description of enzyme-independent production ofNO on the skin
surface ofman a decade ago(Weller et al., 1996), the range of functions in skin in
which the involvement ofNO has been described has grown. Topical NO donors
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have been shown to be mediators in the treatment of cutaneous fungal and viral
disease(Ormerod et al., 1999a;Weller et al., 1998), Raynaud's phenomenon(Tucker
et al., 1999), diabetic wound healing(Witte et al., 2002b) melanogenesis(Romero-
Graillet et al., 1996;Romero-Graillet et al., 1997) and the control of keratinocyte
apoptosis following UVR(Weller et al., 2003;Suschek et al., 1999;Suschek et al.,
2001a). However, the development of topical NO donors for therapeutic uses such as
the encouragement ofwound healing, or as anti-apoptotic agents, has been
discouraged by the early suggestion that it might be a potent inducer of
inflammation. The advent ofZe-NO, a donor of pure gaseous NO, now allows me to
revisit the question ofNO's effects on healthy human skin.
3.2. Aims
The aim of this study was:
• To elucidate the inflammatory properties ofNO




• To investigate the observed inert properties ofZe-NO as an NO donor, and
therefore the use ofZe-NO for manipulation of the NO environment in future
studies.
3.3. Methods




Four individual studies were performed, each using healthy volunteers:
• Determination ofbiologically equivalent doses ofZe-NO and acidified NCV -
three subjects.
• Assessment of cutaneous inflammation following application of topical NO
donors - six subjects (three male).
• Determination of NO delivery to the superficial dermis by NO donors - six
subjects (three male).
• Measurement of IL-4 in epidermal suction blister fluid - three subjects. Four
subjects participated in the study measuring IFN y levels (three applied Ze-
NO with two of the three and one additional volunteer repeating the
procedure to attain control samples).
3.3.2. Determination ofbiologically equivalent effects ofZe-NO and
acidified NO2"
It has previously been shown by our group that dermal blood flow correlates directly
with the concentration ofNO delivered transepidermally from topically applied
RSNO NO donors(Seabra et al., 2004). Using this technique the concentrations of
acidified NO2" and Ze-NO which would deliver the same amount ofNO to human
skin were determined. Biologically equivalent concentrations of acidified NO2", and
Ze-NO, were determined by assessing the erythema induced by application of
varying volumes, and concentrations, of each product. Both products were
reconstituted in aqueous cream BP®: acidified NO2" 0.5%, acidified NO2" 5% (each
with 2% ascorbic acid), and Ze-NO 20%, 30%, 40% and 50%. Either 0.02ml or
0.04ml of the topical donors were applied to a 1cm2 area on the volar forearm, the
area was covered with tegaderm™ (3M Health Care, St Paul). Laser doppler probes
were secured to the tegaderm overlying each application. Cutaneous blood flow,
measured as red blood cell flux using a laser doppler perfusion monitor (Moor
Instruments Ltd, Axminster, UK), was used as an index of erythema. The laser
doppler unit consisted of one main unit and two satellite units connected to the
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server, thus allowing flux readings from three laser probes to be recorded
simultaneously. The perfusion monitor was connected to a PC and recordings
displayed continuously by MoorSoft for windows/moorLAB vl.31 (Moorsoft
Instruments Ltd). At three minute intervals for 120 minutes, real-time recording was
paused and the mean blood flow was recorded, a mean of three ten second duration
readings was taken at each three minute interval.
3.3.3. Preparation and application of topical NO donors
To assess cutaneous inflammation following topical NO donor application the
following formulations were prepared using aqueous cream BP® as a vehicle:
1. 0.02ml Zeolite zinc (33% wt/wt)
2. 0.02ml Zeolite manganese NO (33% wt/wt)
3. 0.04ml Acidified NCV, ascorbic acid (2% wt/wt) + NO2" (5% wt/wt)
4. 0.02ml Ascorbic acid (2% wt/wt)
N02"was not tested alone. Each preparation was applied to a 1cm2 area of skin on the
volar aspect of the forearm eight hourly for two consecutive days. The last
application of cream was made 12 hours before assessment of the response and
biopsy.
3.3.4. Tissue specimens
Forty-eight hours after application of the NO donors and control 4mm full thickness
skin punch biopsies were taken from the centre of each site of topical application.
Tissues were embedded in paraffin and 4pm sections were cut. Sections were stained
with haematoxylin-eosin (H&E) or processed for immunohistochemical staining
using a Dako EnVision™ K5007 system (DakoCytomation Carpintera, California)
with subsequent 3,3'diaminobenzidine (DAB) incubation. The EnVision™ system is
a two-step procedure: the primary antibody incubation is followed by incubation with
an enzyme and antibody labelled inert 'spine' molecule of dextran.
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3.3.5. Immunohistochemical quantification of inflammation in epidermis
and dermis post topical NO donor application
A panel of antibodies were used for immunohistochemical stainings: CD la - Dako
M3571, CD3 - Dako A0452, CD4 - Novocastra NCL-L-CD4-368 (Novocastra,UK),
CD8 - Dako M7103, CD68 - Dako M0876, myeloperoxidase - Dako A398 (for
neutrophils and other myeloid cells). Following incubations with the primary
antibody and Envision the peroxidase label is visualised with Dako DAB solution
with hydrogen peroxide substrate at pH 7.4. Finally slides were counterstained in
Haematoxylin before coverslipping. For analysis of the staining results and
preparation of images a multi-colour microscope (Leitz), Q imaging monochrome
camera and Q Capture Pro computer software (Media Cybernetics, UK) were used.
Positive and negative cells were counted by a blinded observer at high magnification
using a x40 objective lens.
3.3.6. Quantification ofNO delivery to superficial dermis using cutaneous
microdialysis
In six subjects, dermal microdialysis catheters were used to measure NO
concentrations within the superficial dermis. Six microdialysis catheters were
inserted into the superficial dermis of the anaesthetised sites (two at each site).
Noradrenaline was dialysed through each catheter at a rate of2pL/min. The infusion
of noradrenaline was maintained throughout the experiment in order to prevent the
removal ofNO by the cutaneous microvasculature. Dialysate was collected
continuously in aliquots covering 15 minute periods. Samples were immediately
stored at -70°C for future analysis. Following insertion of the microdialysis catheters
dialysate was collected for 30 minutes prior to the application of: 0.02ml Ze-NO
(catheters 1 and 2), 0.04ml acidified NO2" (catheters 3 and 4) and 0.02ml aqueous
cream (catheters 5 and 6), thereafter sampling was continued for a further 90 minutes
in 15 minute aliquots.
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3.3.7. Determination ofMV concentration in dialysate
All dialysate samples were analysed within 24 hours of collection. Nitrite
concentrations were determined by reductive denitrosation by an iodide/triiodide
containing reducing mixture and subsequent measurement of the gaseous NO
released by its chemiluminescent reaction with O3 (Ch2.5).
3.3.8. Identification of CD4+ Th cell-type in epidermal suction blister fluid
For analysis of IL-4 and IFN y in suction blister fluid volunteers applied 33% Ze-NO
and aqueous cream to two separate 25cm2 areas on the volar aspect of the forearm.
Applications were repeated eight hourly for 48 hours after which topical applications
were removed and skin was cleaned with an alcohol wipe (Alcotip swab, Universal
Hospital supplies Ltd, UK). Five 5mm diameter epidermal suction blisters were
created overlying each of the two sites of topical application. IL-4 and IFN y
concentrations in epidermal blister fluid were analysed using Human IL-4 and
Endogen Human IFN y ELISA kits (Pierce Biotechnology, Inc., Rockford, IL).
Protein concentrations of epidermal suction blister fluid were determined. All results
were expressed as cytokine concentration (pg) per mg protein.
3.4. Results
3.4.1. Topically applied Ze-NO (0.02ml of 33%) and acidified NO2" (0.04ml
of 5%) produce similar increases in dermal blood flow and NO
Our group have previously shown that dermal blood flow correlates directly with the
concentration ofNO delivered trans-epidermally(Seabra et al., 2004). A range of
different concentrations of acidified NO2 and Ze-NO were applied to a 1cm2 area on
the volar forearm, subsequently blood flow was measured at each site. Based on this
bioassay, 33% Ze-NO was found to produce comparable effects on dermal blood
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Figure 3.1 Erythema measured with a laser Doppler flow meter following application of topical 33%
Ze-NO and 5% acidified NOi (n=6, ± SEM)
Microdialysis was then used to measure transepidermal NO diffusion by these two
donors (figure 3.2). Dialysate was collected continuously for 60 minutes in four
equal aliquots of 15 minutes each. Nitric oxide is oxidised to NO2" in aqueous
solution, the dialysate NO2" was reduced back to NO by tri-iodide reduction and
'stripped' in nitrogen carrier gas to the chemiluminescence analyser for analysis. As
with erythema development, comparable release ofNO was observed between the
two different NO donors, although slightly higher concentrations ofNO were
















0.02ml zeolite NO 0.04ml acidified nitrite
Figure 3.2NO delivered to superficial dermis by topical 33% Ze-NO and 5% acidifiedNOf
measurements made by chemiluminescence analysis ofcutaneous microdialysatefluid (n=6, ± SEM)
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3.4.2. Acidified NCf" causes marked erythema, oedema and ulceration in
comparison with Ze-NO and controls
In all six subjects clinical inflammation was observed at the sites of acidified NCf"
application with significant discomfort, erythema, oedema and superficial cutaneous
ulceration. This developed in the first 36 hours of application. A representative
example is shown in figure 3.3. The Ze-NO used contains the metal ion manganese
(Mn) which induced orange discolouration, attributable to the delocalized electrons
within the metal-ligand Mn-NO bond, but there were no clinically visible changes or
discomfort consistent with inflammation.
2% ascorbic acid 5% acidified nitrite 33% zeolite NO 33% zeolite
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Figure 3.4 H & E and immunohistochemical staining ofskinfollowing topical application of33% Ze-




3.4.3.1.AcidifiedNOf, but not Ze-NO, causes infiltration ofmacrophages
and neutrophils into the epidermis
A significant increase in macrophages and neutrophils was seen in the epidermis,
following the application of topical acidified NO2" compared with it's own control
(2% ascorbic acid), zeolite control and Ze-NO (figure 3.4 & 3.5 ).
3.4.3.2.AcidifiedNO2 but not Ze-NO, reduces Langerhans cells in the
epidermis
A highly significant loss of Langerhans cells from the epidermis was seen following
topical application of acidified NO2". This finding was significantly different to that
seen with the ascorbic acid control, Ze-NO, and Zeolite alone (figure 3.4 and 3.5).
32 :
CD1a CD3 CD4 CDS CD68 Neutrophils
Figure 3.5 Inflammatory cells in the epidermis following application of33% Ze-NO, 5% acidified
N02 and controls, quantified by immunohistochemical staining (n=6, ±SEM)




3.4.4. l.Both acidifiedNOf and Ze-NO result in a moderate increase in
dermal T cells
A significant increase in dermal CD3, 4 and 8 positive T cells was seen following
topical application of acidified NO2", a less marked but significant increase was seen
in CD 4 positive T cells following topical application ofZe-NO (figure 3.4 & 3.7).
Suction blister fluid in Ze-NO treated skin had significantly increased IFN y when
compared with control blister fluid (mean control 0.1±0.07pg/mg protein, mean IFN
y 0.6±0.4pg/mg protein, figure 3.6), there was no detectable IL 4 (data not shown).
While CD4 can be expressed on macrophages, the finding of elevated IFN y in
association with CD3 and CD4 positive cells strongly suggests the presence of




Figure 3.6 ELISA analysis ofepidermal suction blisterfluid, data shows IFN y concentration in
epidermal suction blisterfluid after correction forprotein concentration
n=4, mean ± SEM, control O.lOpg/mgprotein, Ze-NO 0.57pg/mgprotein, p<0.05
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3.4.4.2.AcidifiedNOf causes infiltration ofmacrophages and neutrophils
into the dermis
A significant increase in macrophages and neutrophils was seen in the dermis
following topical acidified NO2" application in comparison with acid control and both







Figure 3.7 Inflammatory cells in the dermisfollowing application of33% Ze-NO, 5% acidified N02~
and controls, quantified by immunohistochemical staining
*a acidifiedNO! compared with all otherpreparations, p<0.05. *b acidified N02~ comparedwith acid
and zeolite controls, p<0.05. *c Ze-NO compared with zeolite control, p<0.05.
3.5. Discussion
Acidified NO2" produced by the combination ofNO2" and ascorbic acid has potent
inflammatory effects on human skin in vivo as Ormerod initially showed(Ormerod et
al., 1999a), and as has been confirmed in these experiments. I suggest that acidified
NO2" is not an ideal topical NO donor, as in addition to NO it also releases a number
of other potentially pro-inflammatory mediators.
The chemically simplest form of acidified NO2" is sodium NO2" to which




NOy + H+ ^ — HN02
2HN02 ■ «, N203 + H20
N203 NO- + N02
Figure 3.8 AcidifiedNO2 is formed by mixing sodium NO2 with hydrochloric acid which releases NO
The weak acid ascorbic acid may seem to the non-chemist like an ideal candidate for
a formulation of acidified N02", but the reaction between ascorbic acid and sodium
N02", which also gives NO, is different to that described above(Dahn et al., 1960)
(figure 3.8). When ascorbic acid and N02" are mixed, the N203, formed from N02"
and H+, is reduced with subsequent release ofNO and ascorbyl radicals (figure 3.9).
2HN02 N203 + H20
HO OH ONO OH
radical
Figure 3.9 Ascorbic acid andNO2' when placed on the skin form N2O3 from NO2 andH', this is
reduced with subsequent release ofNO and ascorbyl radicals
I suggest it is these ascorbyl radicals, and additional species formed downstream of
them, which give the N02"-ascorbic acid mix such potent pro-inflammatory
properties. We hypothesise that the ascorbyl radicals within the cream diffuse into
the skin, alternatively endogenous ascorbate may also form radicals within the skin.
In addition to being an inflammatory stimulus itself, the ascorbyl radical has the
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potential to form further pro-inflammatory species: a) in the presence of oxygen, pro¬
inflammatory hydrogen peroxide is formed (figure 3.10).
HO hydrogen
peroxide
Figure 3.10 In the presence ofoxygen the ascorbyl radical has the potential to form hydrogen
peroxide
b) The ascorbyl radical may react with cysteine or tyrosine to give cysteinyl or
tyrosyl radicals, c) the ascorbyl radical may also react with lipids in cell membranes













Figure 3.11 The ascorbyl radical may react with lipids in cell membranes producing a pro¬
inflammatory hydroxyl radical
In contrast to acidified NO2", Ze-NO produces effects caused directly by NO itself.
Zeolite based compounds are already used clinically as MRI gastrointestinal contrast
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agents and as clotting enhancers. Zeolite-A (LTA) consists of alternating Si04 and
AIO4 tetrahedra that share corners to produce an open framework (figure 1.14). It has
a natural affinity for NO which is bound within the framework, and NO is released
(delivered) from this stable storage material in biologically relevant amounts on
contact with water. Ze-NO has anti-thrombotic properties, by inhibiting platelet
aggregation and adhesion in plasma(Wheatley et al., 2006). The release kinetics of
NO from zeolites can be tailored by altering the type and number ofmetal cations in
the structure, allowing NO delivery patterns to be modulated to specific clinical
requirements. In preliminary experiments looking at different formulations ofZe-NO
it was found that using manganese (Mn) or cobalt (Co) within the zeolite structure
led to a more prolonged release ofNO than other cations. Mn-Ze-NO was selected
for use in the main experiments as cobalt may induce an allergic contact dermatitis.
The Langerhans' cell number was shown to be greatly decreased in the epidermis of
skin treated with acidified NO2", compared to that treated with Ze-NO or vehicle
controls (figure 3.5). Langerhans' cells are bone marrow-derived antigen-processing
and presenting cells that are involved in a variety of T cell responses. They are the
primary cells in the epidermis that are responsible for the recognition, uptake,
processing, and presentation of soluble antigen and haptens to sensitised T
lymphocytes. Langerhans cells in the epidermis can ingest and process antigens, they
then migrate to the draining lymph node. Activated Langerhans' cells that have been
induced to migrate after contact with antigen are potent stimulators of naive T cells. I
interpret the marked reduction of Langerhans' cells in the epidermis of skin treated
with acidified NO2" as a further indication of the inflammatory properties of this
topical preparation, it is postulated that acidified NO2" induces a massive migration
of Langerhans' cells to their draining lymph nodes. An alternative explanation to this
reduction in Langerhans' cell number, is that topical acidified N02" is responsible for
inducing such an intense inflammatory reaction that the epidermis itself is disrupted,
and hence Langerhans' cells are simply shed within the epidermis that is lost.
Certainly some epidermal disruption can be seen both clinically and histologically in
the sections of skin treated with acidified N02" (figure 3.3 & 3.4). Langerhans' cell
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migration is also a characteristic finding following UV radiation and a component of
UV induced immunosuppression. NO has been shown to be a mediator of
Langerhans cell migration in UV radiation induced immunosupression to nickel
contact hypersensitivity(Kuchel et al., 2003). In the experiments detailed in this
chapter, Ze-NO produced a small, but non-significant fall in Langerhans' cell
density. The degree of reduction in Langerhans' cells is almost certainly dose
dependent, as Kuchel was using 5 MED's of solar simulated radiation(Kuchel et al.,
2003), while the erythema (and thus NO delivery) produced by our Ze-NO donor
was equivalent to 0.75-1MED.
The majority of significant inflammatory cell infiltration occurred in the dermis as
opposed to the epidermis. Ze-NO induced a mild Thl infiltrate whereas acidified
NO2" produced a much greater mixed infiltrate ofCD3, 4, 8, and 68 positive cells
and neutrophils. The charge neutrality ofNO facilitates its free diffusibility through
aqueous solutions and across membranes. NO released from Ze-NO can thus diffuse
across the epidermis to the dermis to exert its biological effects, where it can be
oxidised to form aqueous NO2", an active storage form ofNO which serves to
prolong its activity.
The data presented in this chapter give a clear indication that NO from Ze-NO leads
to a CD4 positive lymphocyte infiltration of the skin (figure 3.4 & 3.7), with IFN y
cytokine secretion typical of Thl lymphocytes (figure 3.6). Great care has been taken
in these experiments to ensure that the amounts ofNO delivered to the skin by Ze-
NO match that of acidified NO2", this comparability was ensured by measuring both
NO donor induced changes in dermal blood flow and also dermal NO2" concentration
by microdialysis (figure 3.1 & 3.2). Data obtained from these studies would suggest
that the biological effects ofNO itself are more specific and limited than was




Psoriasis is characterised by a CD4 positive T lymphocyte infiltration to the upper
dermis(Baker and Fry, 1992) with a predominantly Thl pattern of cytokine secretion,
and by hyperproliferative, poorly differentiated keratinocytes in the epidermis. The
iNOS enzyme is consistently found in the dermis and basal epidermis of psoriatic
plaques(Bruch-Gerharz et al., 1996;Rowe et ah, 1994), and the characteristic
erythema seen clinically, indicates vasodilatation and thus presumably biologically
significant NO production. Measurements with a chemiluminescence meter from the
surface of psoriatic plaques show elevated NO release(Ormerod et ah, 1997), and
serum NO2", an indicator of systemic NO production, is elevated in psoriatics with
active disease(Tekin et ah, 2006). However, it has been suggested more recently that
the role ofNO in psoriasis is more complex than can be explained simply by an
upregulation of iNOS. The effects ofNO are frequently dose dependent, but in a
non-linear fashion with opposing effects seen at low and high concentrations.
Although iNOS is upregulated in psoriatic plaques, the generation ofNO is
maintained at relatively low concentrations due to a concomitant upregulation of
arginase 1. Arginase 1 competes for the common substrate L-arginine (figure 1.3),
thus maintaining NO at relatively low levels despite the observed upregulation of
iNOS. It has been shown that relatively low levels ofNO promote keratinocyte
proliferation, consistent with the histological picture ofpsoriasis, whereas higher
levels ofNO arrest cell proliferation and initiate differentiation(Krischel et ah, 1998).
The pleiotropic nature ofNO in influencing keratinocyte proliferation is also
observed when studying T cells. Niedbala et al. have shown that NO, in a low
concentration, up regulates IL-12R(32 expression on naive T cells, which allows for
induction of Thl cells but has no influence on Th2 cell differentiation(Niedbala et
ah, 2006). The selective enhancement ofThl differentiation by NO is dependent on
it being at low concentration, with high NO concentrations being cytotoxic to this T
cell population. The data obtained from the experiments in this chapter are consistent
with this observation, and provide early evidence to show Thl lymphocyte
infiltration induced by relatively low concentrations ofNO in vivo in man. The Ze-
NO preparation used in the experiments detailed in this chapter produced a just
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perceptible erythema, consistent with the erythema observed after one MED UVB,
and therefore a biologically relevant and relatively low concentration ofNO.
In summary the data provided in this chapter suggest that Ze-NO is an effective NO
donor in man, and does not exhibit the dramatic pro-inflammatory effects which
were previously attributed to NO. The data presented concurs with Kolb-Bachofen's
hypothesis that iNOS activity in psoriatic plaques produces a relatively slight
elevation in NO levels owing to substrate competition by arginase 1. A moderate Thl
cell response is induced by these low concentrations ofNO, which is in keeping with
current views on the role ofNO in the regulation of T cell functions(Niedbala et al.,
2006). It has been shown that an ascorbic acid-NTV combination is a potent pro¬
inflammatory mix, a number ofmediators in addition to NO are potentially active in
this process (figures 3.9-3.11). Ze-NO has been demonstrated to be an effective
topical NO donor that releases physiologically relevant concentrations ofNO. It has
been vital to find such an NO donor before I can progress to the investigations
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4. CHAPTER 4 - NO STORES IN HUMAN SKIN
4.1. Introduction
Three NOS enzymes have been isolated, these are responsible for enzyme-dependent
NO formation(Moncada and Higgs, 1993). Two constitutive and one inducible NOS
isoenzyme exist, each ofwhich has been isolated in human skin(Baudouin and
Tachon, 1996;Becherel et al., 1994;Bull et al., 1996;Romero-Graillet et al.,
1996;Sakai et al., 1996;Wang et al., 1996). The t1/2ofNO (0.05-
1.18milliseconds)(Borland, 1991;Liu et al., 1998;Vaughn et al., 2000) is very short,
and thus it was initially regarded as having actions only in close proximity to its site
ofproduction. It is now accepted that NO can form additional bioactive stable
carriers/donors in the blood and tissues by reacting with SH groups to form
RSNOs(Stamler et al., 1992b;Stamler et al., 1992a). These regulate proteins by S-
nitrosation of specific cysteine residues(Hess et al., 2001). A major proportion of
endogenous NO is also inactivated by oxidation to NO2" and the more stable NO3".
It has recently become possible to quantify NO-related products in biological
samples, using a technique of gas-phase chemiluminescence(Feelisch et al., 2002).
Paunel et al., have used this technique to quantify NO-related products in ex-vivo full
thickness human skin specimens(Paunel et al., 2005). Paunel et al., have also shown
evidence to suggest that UVA irradiation induces rapid photolysis ofRSNO and
NO2". The photolysis ofNO-related products in human skin leads to high output
enzyme-independent NO production, which occurs within 20 minutes after the onset
ofUV exposure(Paunel et al., 2005).
NO reduces UV induced apoptosis in mouse dermis and epidermis(Weller et al.,
2003), and a protective role of iNOS has also been shown in endothelial cells in vitro
following UVA irradiation(Suschek et al., 1999). It has been hypothesised that the
rapid UVR-induced, enzyme-independent release ofNO from NO-related products in
human skin, is biologically important. This photolytic release from NO stores
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potentially 'bridges the gap' between UV challenge and the enzymatic up-regulation
and activity of iNOS, which is maximal 8-10 hours post irradiation(Paunel et al.,
2005) (figure 1.13).
4.2. Aims
The aim of this study was:
• To quantify NO-related products in human skin in vivo:
o In sweat on the skin surface
o In epidermis
o In superficial vascular dermis
• To determine in vivo the extent to which NO release can be demonstrated
during UVA irradiation.
4.3. Methods
All methods common to more than one study are detailed in Chapter 2.
4.3.1. Study volunteers
Three individual studies were performed, each using healthy volunteers.
• Quantification ofNO-related products in epidermal suction blisters and
blister fluid - ten subjects, age range 22-41 years, three male.
• Quantification ofNO-related products in human sweat, plasma and saliva -
ten subjects, age range 20-29 years, six male.
• Quantification ofNO-related products in the superficial vascular dermis -
eighteen subjects, fourteen of these also underwent UVA irradiation during
cutaneous microdialysis and eight had plasma NO2" measured at the time of
their microdialysis. Age range 20-50 years, four male.
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4.3.2. Saliva and Plasma Collection
One hour prior to commencing sweat collection and cutaneous microdialysis,
samples of venous blood (5ml) were taken from each subject. Samples of saliva
(3ml) were also taken from subjects attending for the sweat study. Blood and saliva
samples were stored in NEM/EDTA solution and centrifuged immediately at 1300g
for eight minutes. Supernatants were collected and stored at ~70°C for a maximum of
three days before analysis.
4.3.3. Sweat Collection
An anaerobic method of sweat collection was used which allows for the collection of
relatively large volumes of sweat with minimal epidermal contamination(Boysen et
al., 1984). Subjects were taken to the Edinburgh commonwealth pool sauna in order
to perform adequate sweat collection at rest. Sweat samples were collected into
eppendorfs containing NEM/EDTA and stored at "70°C for a maximum of three days
before analysis.
Figure 4.1 Method ofanaerobic sweat collection from human skin
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Dermal microdialysis catheters were used to measure NO concentrations within the
superficial dermis and to quantify NO release following UV exposure. Two sites, one
on the volar aspect of the forearm and the second on the flexor aspect of the upper
arm, were anaesthetised. Four microdialysis catheters were inserted into the
superficial dermis parallel with the skin surface at each of the two anaesthetised sites.
Normal saline was dialysed continuously through two catheters at each site,
noradrenaline was dialysed continuously through the two remaining catheters at each
site. Dialysate was collected continuously in 15 minute aliquots. Following insertion
of the microdialysis catheters dialysate was collected for 30 minutes prior to the
onset of UVA exposure. Catheters in the volar forearm were irradiated with UVA
whereas those in the flexor aspect of the upper arm remained unirradiated.
Figure 4.2 Cutaneous microdialysis during UV exposure
4.3.5. UV source
The UVA source used was a bespoke cabinet containing a panel of 12 bulbs (Philips
TLK 40W/10R R-UVA, Philips Hamburg, Germany) emitting a UVA spectrum 350-
400nm, peak 360nm, 10mW/cm2 (figure 1.9). Volunteers were positioned so that the
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skin to be irradiated was parallel to the light source and irradiated for 60 minutes
(60J/cm2).
4.4. Results
4.4.1. The concentration of total NO-related products in human saliva is ten
times greater than that in the superficial vascular dermis, plasma and
sweat
The concentration of total NO-related products in saliva (267 ± 194.67pM) was
significantly greater than that found in human superficial vascular dermis (12 ±












Superficial Plasma (n=18) Saliva (n=10) Sweat (n=10)
dermis (n=18)
Figure 4.3 Total NO-relatedproducts in human superficial vascular dermis, plasma, saliva and sweat
Boxplots represent median and interquartile range, 'maximum andminimum values, • mean.
These findings are consistent with those of Lundberg et al., who found the mean
salivary N03~ and NO2" concentrations of nine subjects to be 0.19mM and 104pM
respectively. The same nine subjects had plasma NCVand NO2" concentrations of
30pM and 123nM respectively(Lundberg and Govoni, 2004) (table 4.1). Ingested
NO3" is absorbed from the gastrointestinal tract into the blood stream where it mixes
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with endogenously synthesized NO3". Most N03" is excreted in urine but some is
secreted in saliva, sweat and the gastrointestinal tract(Lundberg and Govoni, 2004).
The high salivary concentrations of total NO-related products are explained by this
enterosalivary circulation (figure 1.6), in which up to 25% of plasma NO3" is taken
up by the salivary glands and secreted with saliva(Spiegelhalder et al., 1976).
Microorganisms such as those found on the tongue surface can anaerobically reduce
NO3" to NO2" (Lundberg and Govoni, 2004). On passing to the stomach, acidification
ofNO2" releases large amounts ofNO and other RNSs.
4.4.2. NO3" accounts for the majority of the total NO-related products in
saliva, plasma, sweat and epidermis.
In all biological samples in which individual NO-related products were quantified
NO3" was found to be the predominant species. Sixty to seventy-five percent of
plasma, saliva and sweat total NO-related products was NO3", with the majority of
the remainder being NO2" (figure 4.4).
A RSSNG's + RNNOs
□ Nitrite
0 Nitrate
Figure 4.4 The proportion ofindividual NO-relatedproducts found in human saliva, plasma and
sweat
NOT is the predominantNO-relatedproduct contributing to 60-75% ofthe total, NOT makes up
the majority ofthe remainder (24-39%), negligible amounts ofRS/NNOs were found (0-1%).
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A similar proportional split between NO3" and NO2" to that seen in saliva, plasma and
sweat, was observed when measuring individual NO-related products in epidermal
suction blisters and blister fluid (figure 4.5).
Figure 4.5 Suction blisterfluid contains negligible NO-relatedproducts compared to epidermis
Mean total NO-relatedproducts epidermis 0.03 ± 0.03pmol/mgprotein, mean total NO-related
products suction blisterfluid 0.004 ± 0.007pmol/mgprotein, n=10, error bars = SEM.
Epidermal suction blister data is displayed as pmol/mg protein and therefore not
directly comparable to the other biological species measured. Paunel et al., are the
only other group to have measured NO-related products in human skin. In contrast to
my data they used ex vivo full thickness frozen sections(Paunel et al., 2005).
Following adjustment ofmy data to pM NO2" with equivalent protein concentrations,
my results are comparable with those of Paunel et al., (table 4.1). In addition to
analysing epidermis from the roof of suction blisters, blister fluid was also examined
for the concentration of NO-related products. In contrast to the epidermis, epidermal





Measured using NO2" standards
Total NO-related
products N03 N02 RSNOs&RNNOs
Saliva (n=10) 267.13 197.38 69.55 0.21
Plasma (n=10) 27.38 20.60 6.59 0.20
Sweat (n=10) 21.97 13.13 8.66 0.19





Saliva(Lundberg and Govoni, 2004) 294.03 190.00 104.00 0.03
Plasma(Lundberg and Govoni, 2004) 30.13 30.00 0.12 0.01
SweatfWelleretal., 1996) 43.12 39.70 3.42 not measured
Measured as pmols n02"/mg protein
Total NO-related
products n03 no2 RSNOs&RNNOs
Epidermis 0.0289 0.0278 0.0008 0.0003
Epidermal suction blister fluid 0.0036 0.0031 0.0005 0
Epidermis adjusted to compare with
Paunel data (pM N02") 278.15 8.37 2.89
Epidermis & dermis (pM N02~)(Paunel
et a!., 2005) 82.4 5.1 2.6
Table 4.1 Summary ofthe concentration ofNO-relatedproducts at different sites and comparison
with published data (shown in italics)
4.4.3. The concentration of total NO-related products in human plasma
corresponds to one third of the concentration of total NO-related
products in sweat and two thirds of the concentration of total NO-related
products of the superficial dermis.
The concentration of total NO-related products in human sweat and plasma was




Regression analysis suggests that the concentration ofNO-related products in plasma
is linked to the concentration ofNO-related products found in sweat (R2 = 0.34,
figure 4.6a) and in the superficial dermis (R2 = 0.62, figure 4.6b).
y = 0.4166x + 5.3713
R2 = 0.6172
20 40 60
PI.iariatot.il NO relator! pro ducts (tiM)
a) sweat NO-relatedproducts
10 20 30 40 50 60
Plasna total NO-ielated pioductstuM)
b) dermal NO-relatedproducts
Figure 4.6 Relationship between plasma NO-relatedproducts and a) sweat NO-relatedproducts, b)
dermal NO-relatedproducts
Paunel et al. have demonstrated a correlation between the concentration ofNO2" and
RSNOs in the skin and the formation ofNO from the skin within 20 minutes of
exposure to UVA(Paunel et al., 2005). Taking the findings of Paunel et al., into
consideration I hypothesise that plasma NO-related products may partly determine an
individual's response to UVA exposure.
4.4.4. The concentration of total NO-related products vary between
individuals
Cutaneous microdialysis was used to quantify aqueous NO-related products in the
superficial vascular dermis in vivo. Over a 90 minute period of sampling, using
normal saline as dialysate fluid, the concentration of NO-related products showed
minimal variation within subjects (figure 4.7). There was however an approximately
four fold inter-individual variation in total NO-related products of the superficial
dermis (median 10.49pM, IQR 6.3pM, figure 4.3 and 4.7), which is consistent with
the known wide variation in levels of tissue NO-related products observed following
NO2" and NO3" intake(Gladwin et al., 2005).
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Figure 4.7 Aqueous NO-relatedproducts in the superficial dermis over a 90 minuteperiod of
sampling
Mean dermal concentration ofNO-relatedproducts is represented by ♦.
Mean 12.31 ± 5.97pM, error bars = SEM (n=18)
4.4.5. UVA irradiation increases the yield of aqueous NO-related products
from the superficial vascular dermis. This is reduced by local
vasoconstriction
The yield of aqueous NO-related products from the superficial dermis was lower on
dialysing with noradrenaline than normal saline. UVA irradiation significantly
increased the yield of total NO-related products from the dermis after 30 minutes
when normal saline was used as a dialysate, this was abrogated when noradrenaline
was used as a dialysate. Mean total NO-related products of the superficial dermis
during irradiation: unirradiated normal saline 12.49 ± 0.64pM, irradiated normal
saline 15.50 ± 0.93pM, unirradiated noradrenaline 11.12± 1.02pM, irradiated






















Figure 4.8 NO-relatedproducts in the superficial dermisfollowing UVA exposure, comparison
between normal saline and noradrenaline as dialysate
Unirradiated normal saline (n=18), irradiated normal saline (n=14), unirradiated noradrenaline
(n=12), irradiated noradrenaline (n=ll). *p<0.05 on comparison ofunirradiated with irradiated
using normal saline as dialysate, error bars = SEM.
The cumulative concentration of total NO-related products during the period of
irradiation was significantly higher in the irradiated than unirradiated skin when
dialysed with normal saline, but there was no significant difference when
noradrenaline was used as dialysate (figure 4.9). These findings suggest that the
superficial dermal vasculature is important in the delivery ofNO and NO-related
products to the skin following UVA exposure.
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UnirracMed Irradiated NaCI Unirradiated
NaCI NAd
Irradiated NAd
Figure 4.9 Sum ofNO-relatedproducts in the superficial dermis duringperiod ofUVA exposure,
comparison between normal saline and noradrenaline as dialysate
Unirradiated normal saline (n=18), irradiated normal saline (n=14), unirradiated noradrenaline
(n=12), irradiated noradrenaline (n=ll). *p<0.05 on comparison ofunirradiated with irradiated
using NaCI as dialysate, error bars = SEM.
4.4.6. UVA exposure induces NO release within the superficial vascular
dermis which is maximal 30 minutes after the onset of exposure
When normal saline is used as a dialysate there is a significant increase in aqueous
NO-related products 30 minutes after the onset ofUVA irradiation (30J/cm2, figure
4.10). These findings are consistent with the data of Paunel et al., who have
demonstrated NO release from ex-vivo human skin specimens maximal 20 minutes
after the onset ofUVA exposure (40J/cm2) (Paunel et al., 2005). Both the in vivo
results of this experiment, and the ex vivo results of Paunel et al., are consistent, they
suggest that UVA exposure results in photolysis ofNO stores in human skin and the
rapid release ofNO. This process is maximal 20-30 minutes after the onset ofUV































Figure 4.10 NO-relatedproducts in the superficial dermisfollowing UVA exposure using normal
saline as dialysate
Data normalized to 30 minute value, n=14, error bars = SEM, *p<0.05.
4.5. Discussion
It is widely accepted that NO-related products in the form ofNO3", NO2" and RSNOs
are important storage forms ofNO, the latter two offering potential sources of
recyclable bioactive NO(Lundberg and Govoni, 2004;Rassaf et al., 2004). Nitrite has
been shown to act as a signalling molecule in its own right(Bryan et al., 2005), and
can also provide a bioavailable pool ofNO during periods of hypoxia and
ischaemia(Wink et al., 1996b;Zweier et al., 1995). RSNOs have also been implicated
as important storage and transport systems for NO. Low molecular weight RSNOs
exert NO-like activity in vz'vo(Ignarro et al., 1981) and circulating RSNOs can release
NO when required(Rassaf et al., 2004). The relative importance ofNO2" and RSNOs
in NO bioactivity continues to be debated, in part fuelled by the different methods
used to quantify these species in blood and tissues. A wide range of basal NO2"
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concentrations in human plasma have been reported, from undetectable to 26pmol/L,
but the majority fall in the nmol/L range(Gorenflo et al., 2001 ;Lundberg and Govoni,
2004;Meulemans and Delsenne, 1994;Moriel et al., 2001;Pelletier et al., 2006;Rassaf
et al., 2002a;Rocks et al., 2005). A similar variation exists for documented quantities
ofRSNOs in human plasma from undetectable to 930nMol/L(Rocks et al., 2005).
The principle explanation for the continued debate regarding the contribution of
individual NO-related products to normal physiology and pathophysiology lies in the
lack of sensitive assays for their detection and the influence that proteins, varying
redox conditions and trace contamination with NOo" may have on these assays.
Chemiluminescence-based detection is a method of quantification of NO-related
products which is simple, sensitive, reproducible and suitable for the analysis of a
high number of samples within a short period of time(Marley et al., 2000), it was
thus ideal for the purpose of the experiments presented in this chapter. Nanomolar
levels in basal NO2" concentration have been found in human plasma using the same
chemiluminescence method as was employed in these experiments. Kleinbongard et
al., compared three different detection methods including chemiluminescence, a
high-pressure liquid chromatography (HPLC) technique and flow injection analysis,
and demonstrated similar concentrations ofNO-related products across species with
all three methods(Kleinbongard et al., 2003).
I have demonstrated that in human epidermis and in sweat on the skin surface NO3" is
the predominant NO-related products, followed by NO2", with only very low
concentrations ofRSNOs being present. Both N03~and N02" are available from
exogenous and endogenous sources. Green leafy vegetables make up 60-80% of the
daily N03" intake of those on a typical western diet(Ysart et al., 1999) whereas NO2"
is used as a preservative for meat and fish(Lundberg and Govoni, 2004). The main
endogenous source ofN03" and NO2" is the L-arginine - NO pathway which is
constitutively active in all cell types in the body. L-arginine is converted to NO by
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iNOS, an enzyme which is upregulated in human skin 8-10 hours after UV
exposure(Kuhn et al., 1998). Nitrite can also be generated from commensal bacteria
in the digestive system by NO3" reduction. An enterosalivary recirculation pathway
exists, with 25% of all circulating NCff being taken up by the salivary glands and
secreted in saliva. The oral cavity contains large numbers ofNCb'-reducing bacteria,
with the result that saliva is the main source ofplasma NCbTBenjamin et al., 1994).
Lundberg et al., have demonstrated that dietary NO3" ingestion influences both
plasma NO3" and NO2" but not RSNO levels(Lundberg and Govoni, 2004).
Interpretation of the data from the experiments presented in this chapter suggests that
the concentration ofNO-related products in an individual's plasma will influence the
concentration ofNO-related products found in their sweat and superficial vascular
dermis. I hypothesise that ultimately dietary NO3" may offer a source for
manipulation of cutaneous NO-related products.
Historically, evidence for the existence of stored forms ofNO dates back to
experiments performed in the 1950s on the relaxant effect of light on vascular
smooth muscle(Furchgott et al., 1961). Photorelaxation in rabbit aorta was shown by
Furchgott et al., to peak near 310nm with a shoulder near 350nm. The role ofNO2" in
photorelaxation was implicated when a dominant peak was shown at 355nm
following incubation with NO2XFurchgott, 1971). More recently Rodriguez et al.,
have shown that in rat vascular tissue RSNOs, RNNOs and NO2" have photoactivity
in vitro but NO3" shows no appreciable activity. They calculated the action spectra
for NO release from RSNOs to be 310-340nm and from NO2" 3 lOnm and
350nm(Rodriguez et al., 2003), both these ranges lie within the spectrum ofUVA.
It has been hypothesised that NO-related products stored in human skin may play a
role in the acute response to UV(Paunel et al., 2005). Paunel et al., demonstrated
formation ofNO due to photo-decomposition ofNO2" and RSNOs maximal within
20 minutes ofUVA exposure of ex vivo full thickness human skin(Paunel et al.,
2005). Taking the findings of Paunel et al., a step forward, I have now demonstrated
this effect in human skin in vivo using cutaneous microdialysis. Dialysate sampling
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of the superficial vascular dermis revealed an increase in NO-related products
maximal 30 minutes after exposure to a biologically relevant dose ofUVA
(30J/cm2). Gaseous NO released within the dermis will undergo oxidative
decomposition on entering the extra-cellular vascular space forming aqueous NO2".
Although both RSNOs and N02" will release NO in the UVA spectrum, the relative
concentrations ofMV and RSNOs that I have demonstrated in human skin, suggest
that N02" is likely to be the predominant photoactive NO-related products. Evidence
suggests that NO may play an anti-apoptotic role in human skin following
UVR(Suschek et al., 1999;Suschek et al., 2003b;Weller et ah, 2003). It is likely that
cutaneous NO-related products offer an immediate enzyme-independent source of
NO, allowing protection within 30 minutes of exposure to UVR. As proposed by
Paunel et al., this enzyme-independent NO release bridges the time gap following
UV exposure before the up-regulation of iNOS and enzyme-dependent NO release is
maximal(Paunel et ah, 2005) (figure 1.13).
Inter-individual variations in the concentration ofNO-related products in human
saliva, plasma, sweat, epidermis and superficial vascular dermis were observed in the
subjects used for this chapter, and were similar in each of the different biological
samples. Gladwin has suggested that the majority ofN02" in tissues originates from
the exogenous intake ofN02" and NO3" and not from endogenous sources, this results
in great variation in tissue NO2" levels. In contrast plasma levels ofN02" vary only
slightly suggesting the existence of regulatory pathways in blood(Gladwin et ah,
2005).
Enzyme dependent NO production occurs in all cell types of human skin by at least
one of the three NOS isoenzymes, NO is produced constantly by the endothelium at
4nM/s(Marley et ah, 2001). 1 have confirmed the presence ofNO-related products in
the dermis and epidermis but I have not isolated the storage site to a particular cell
type. On exposure to UVA a significant increase in aqueous NO-related products is
detected by cutaneous microdialysis, and this increase is reduced in the presence of a
local vasoconstrictor. Both N02" and RSNOs are transported in the bloodstream and
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are susceptible to photolysis by UVA. I suspect that much of the observed increase in
NO-related products following UVA exposure comes directly from the vasculature
but with locally bound stores, also contributing.
Hypertension and ischaemic heart disease (IHD) both correlate with latitude(Fleck,
1989;Rostand, 1997), increasing in incidence with distance from the equator. Much
of this is probably due to racial and dietary factors, and a correlation has also
recently been shown between UV induced Vitamin D synthesis and reduced
IHD(Wang et al., 2008). The data presented in this chapter, shows UVR-induced
release of skin bound NO-related products, I suggest that this as an alternative
mechanism by which UV exposure may have beneficial cardiovascular effects.
I present data which confirms and quantifies the presence ofNO-related products
both in human epidermis, superficial vascular dermis and skin surface sweat. These
species have the capability of releasing NO, and I have demonstrated such release
within 30 minutes ofUVA exposure. I believe these findings to be of great
significance, in the context of the skin as the largest 'organ' of the human body (10-
-3
20dm ), which thus offers a considerable store. I believe that enzyme-independent
NO release is an acute mechanism which serves to prevent UV-induced keratinocyte
apoptosis(Paunel et al., 2005). It is known that plasma NO-related products can be
influenced by dietary intake ofNO3" and I have demonstrated a relationship between
the concentration ofplasma NO-related products and those of the superficial vascular
dermis and sweat. I postulate that an individual's dietary consumption of green leafy










5. CHAPTER 5 - NO and UVR-INDUCED APOPTOSIS, P53
ACCUMULATION, DNA DAMAGE and REPAIR
5.1. Introduction
NO has been shown to have paradoxical effects. Its actions depend on its
concentration, its interaction with other free radicals, metal ions, and proteins and on
the cell type of the organism. NO diffuses readily through the cytoplasm and plasma
membranes over several cell diameter distances. Intracellular NO quickly forms NO-
related products: NO3", NO2", RSNOs or ONOO" (figure 1.1). These NO metabolites
may play an important role in the biological effects ofNO, in particular its genotoxic
effects.
Following the recent publication of a technique allowing detection ofNO-related
products in tissues and biological fluids(Feelisch et al., 2002), NO-related products
consisting primarily ofNO3", NO2" and RSNOs have been quantified in human
epidermis, dermis and sweat on the skin surface(Paunel et al., 2005;Weller et al.,
1996) (Ch4.4.6). Ex-vivo and in-vivo evidence suggests that UVA irradiation induces
photolysis ofRSNO and NO2" stored in human skin with subsequent high-output
enzyme-independent NO formation, this reaches a maximum 20-30 minutes after the
onset of irradiation(Paunel et al., 2005) (Ch4.4.6, figure 4.9-4.11). Following acute
enzyme-independent release ofNO from human skin, UVR induces the upegulation
of iNOS and enzyme-dependent activity becomes important. The upregulation of
iNOS starts 8 to 10 hours after UV irradiation and reaches a maximum at
approximately 24 hours(Kuhn et al., 1998;Suschek et al., 2001b). Enzyme dependent
NO released from the skin following UV irradiation has been shown to be the major
mediator ofUV erythema in man(Rhodes et al., 2001).
The pleiotropic nature ofNO is exemplified when considering its role in cell
apoptosis and DNA damage. NO has been shown to exert cytotoxic effects and
initiate the onset of apoptosis in mammalian cells(Kroncke et al., 1997), however it
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has also been shown to protect against the detrimental actions of superoxide,
hydrogen peroxide and alkyl peroxides(Wink et al., 1996b). NO-induced DNA
alterations may lead to p53 post-translational modifications, accumulation and
activation(Forrester et al., 1996;Messmer and Brune, 1996;Nakaya et al., 2000), thus
contributing to the anti-carcinogenic effects of p53. In addition, NO may modulate
tumour DNA repair mechanisms by up-regulating poly (ADP-ribose) polymerase
(PARP) and the DNA-dependent protein kinase (DNA-PK)(Xu et al., 2002).
However, high levels ofNO can mutate the p53 gene allowing for selective clonal
expansion ofp53-mutant cells, and tumorigenesis(Greenblatt et al., 1994). Recent
evidence suggests that NO has an anti-apoptotic role in skin after exposure to UVR.
iNOS derived NO has been shown to protect rat endothelial cells in vitro against
UVA-induced apoptosis(Suschek et al., 1999). Enzyme independent mechanisms are
also important as the presence ofNO2" in vitro has been shown to protect endothelial
cells from UVA induced apoptosis, in a concentration-dependent manner(Suschek et
al., 2003b). An anti-apoptotic role ofNO has also been demonstrated in murine
keratinocytes in vivo and human keratinocytes in vitro following UVB
exposure(Weller et al., 2003).
The type ofDNA damage induced by UVR depends on the wavelength of the
photons that hit the cell. UVB exposure (290-320nm) results in direct light
absorption by DNA, this induces dimerisation reactions between adjacent pyrimidine
bases and the formation ofDNA PPs (Chi.6.2.4). DNA PPs are characterised by C to
T or CC to TT transitions. The transitions are regarded as 'signature' mutations, only
known to be caused by UV(Brash et al., 1991). CPDs in general and thymine dimers
in particular, are the major DNA PPs. The remainder of PPs are accounted for by 6-
4PPs. 6-4 PPs may be converted into their Dewar isomers upon exposure to near
UVR. All UVR wavelengths have been shown to induce DNA PPs(Douki et al.,
2003;Kobayashi et al., 2001;Mouret et al., 2006;Sheehan et al., 2002). UVB only
contributes to 5% of the UVR reaching the earths surface, the remainder being
composed ofUVA (320-400nm). However, UVB induces the majority ofDNA
damage due to the strong absorption ofDNA at UVB wavelengths(Douki et al.,
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2003). CPD formation in skin has been shown to peak at wavelengths near
300nm(Chadwick et al., 1995;Freeman et al., 1989), although mean levels following
narrow band (NB) UVB exposure (31 lnm) were found to be comparable to those
induced by broad band (BB) UVB (295-320nm)(Snellman et ah, 2003).
Critical proteins involved in the response to DNA damage include the p53 tumour
suppressor protein. p53 is an important transcriptional factor and also directly reacts
with proteins such as NER-associated regulatory proteins. Upon activation of p53,
cells have two possible outcomes(Chow and Tron, 2005), cell cycle arrest with:
• DNA repair
• Apoptosis
Evidence for the involvement of PPs in skin carcinogenesis is provided by the
finding of C to T and CC to TT tandem mutations in p53 tumour suppressor genes
isolated from skin tumours(Brash et ah, 1991;Brash et ah, 1996;Dumaz et ah,
1993;Ziegler et ah, 1993). Mutated p53 is unable to induce apoptosis, therefore
allowing for the persistence ofDNA damaged cells and mutagenesis. The lack of
repair of PPs in XP further indicates an association between DNA photodamage and
skin cancer (Dumaz et ah, 1993;Nakazawa et ah, 1994;Ziegler et ah, 1993). In XP
patients the incidence ofNMSC is more than 1000 times greater than in the normal
population.
In the setting ofNO research, translational clinical research is ofparamount
importance ifwe are to accurately determine the role of this pleiotropic free radical
in the processes of: UVR-induced apoptosis, p53 accumulation and DNA




The aim of this study was:
• To determine the influence of physiologically relevant concentrations of
UVR on human skin in vivo, in the presence/absence of exogenous NO, on:
o Apoptosis
o p53 accumulation
o DNA damage and repair
5.3. Methods
All methods common to more than one study are detailed in Chapter 2.
5.3.1. Study volunteers
Two individual studies were performed, each using healthy volunteers.
• To determine the effects of exogenous NO on human keratinocyte apoptosis
and p53 accumulation post UVB - seven subjects, age range 22-44 years, 3
male.
• To determine the effects of exogenous NO on human keratinocyte DNA
damage/repair post UVB - ten subjects, age range 18-35 years, 5 male.
5.3.2. UV source
The UVB source used was a Waldmann UV 801 BL unit (Waldmann, Villingen-
Schwenningen, Germany) which contains a bank of ten TL 20W/01RS fluorescent
lamps (Philips, Eindhovan, Holland). TL 20W/01RS lamps emit a narrow peak
around 31 lnm exclusively. Using this apparatus 1SED ofUVR is delivered over 30




5.3.3. Preparation and application of topical NO donors
For both experiments Ze-NO (33% wt/wt) was used as an NO donor. This is an inert
topical NO donor which we have considerable experience using(Mowbray et al.,
2008). At the time of each application lOOmg ofZe-NO powder was mixed with
200mg aqueous cream BP® and applied immediately to a 4cm2 area on the volar
aspect of the forearm (figure 5.1).
5.3.4. Apoptosis study design
Day 1 - graded doses ofUVB to volar forearm for determination ofMED.
Day 2 - two hours prior to attending the department subjects applied aqueous cream
BP® to one 1 x 4cm2 area (area 1) and Ze-NO to a second 1 x 4cm2 area (area 2),
both on the volar aspect of the non-dominant forearm. After reading of the subjects
MED, topical applications were removed and each area cleaned with an alcohol wipe
(Alcotip swab, Universal Hospital supplies Ltd, UK). An area measuring 1 x 2cm2
was irradiated with 2MED UVB at the distal end of each of areas 1 and 2 (see figure
5.1 for an example of the layout). Aqueous cream BP® and Ze-NO were reapplied
immediately to areas 1 and 2 respectively, subjects continued to apply the topical
formulations eight hourly until their final visit 24 hours later.
Day 3 - twenty four hours following UVB irradiation topical applications were
removed as described previously. One 4mm full thickness skin punch biopsy was
taken from an irradiated and unirradiated site within each of areas 1 and 2 (total of
four biopsies).
5.3.5. DNA damage study design
Day 1 - graded doses ofUVB to volar forearm for determination ofMED.
Day 2 - two hours prior to attending the department subjects applied aqueous cream
BP® to area 1 and Ze-NO to area 2 on the volar aspect of the non-dominant forearm
(figure 5.1). Twenty four hours after being exposed to graded doses ofUVB subjects
attended to have theirMED read. Subjects with the same MED were selected so as to
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minimise inter-individual variation in DNA repair. Topical applications were
removed as described previously. Areas 1 and 2 were irradiated with 2MED UVB,
aqueous cream BP or Ze-NO were reapplied to areas 1 and 2 respectively,
immediately after irradiation. Subjects continued to apply aqueous cream BP' to area
1 and Ze-NO to area 2 eight hourly until their final visit on day 3.
Day 3 - two hours prior to their day 3 visit subjects applied aqueous cream BP® to
area 3 and Ze-NO to area 4 on the volar aspect of the dominant forearm. At their
final visit on day 3 (30 hours following UVB irradiation), topical applications were
removed as described previously. Areas 3 and 4 were irradiated with 2MED UVB.
Following irradiation one 4mm full thickness skin punch biopsy was taken
immediately from each of the four sites 5-8, thereafter one 4mm punch biopsy was









30 hour panel non-dominant volar forearm (4 applications)
2MED Aqueous creamonly
(?) 1 (?) 4cm
4cm
ZeoliteMil NO 2 MED
(?) a™ 2 (7)
15 minute panel, dominant volar forearm (1 application)
Aqueous cream
only
Zeolite Mil NO 2 IMED
(?) Arw 4 (?)
Figure 5.1 Diagrammatic representation ofsites of topical applications, irradiation andpunch
biopsies for DNA damage experiment
The 30 hour pane! represents a similar layout to that used in the apoptosis, p53 study. The fifteen
minute pane! represents maximal DNA damage, approximately 50% repair has taken place by 30
hours.
5.3.6. Histology & Immunohistochemical staining
All 4mm full thickness skin punch biopsies were fixed in 4% buffered formaldehyde
and then processed for histology. Tissues were embedded in paraffin and 4pm
sections were cut. Two sections from each biopsy were stained with H&E, the
remainder were reserved for immunohistochemical (IHC) studies. A Dako
EnVision+ System-HKP (DAB) K4007 was used for IHC staining (DakoCytomation
Carpintera, California). Initially paraffin sections were de-waxed and rehydrated,
following which any endogenous peroxidase activity was quenched by incubating the
specimen with peroxidase block. The specimen was then incubated with primary
antibody, followed by incubation with the labelled polymer. Staining was then
113
Chapter 5
completed by incubation with DAB+ substrate-chromogen, which results in brown
coloured precipitate at the antigen site. Finally, slides were counterstained in
haematoxylin before dehydration and cover slipping. The antibodies used for IHC
staining included:
• Anti-ACTIVE® Caspase-3 pAb (Promega corporation, Madison, USA) -
recognises the cleaved active form of caspase-3.
• Monoclonal Mouse Anti-Human p53 Protein (DO-7 DakoCytomation,
Glostrup, Denmark) - labels both wild-type and mutant p53.
• Anti-Thymine Dimer, clone KTM53 (Kamiya BiomedicalCompany, Seattle,
USA), which stains CPD positive keratinocytes by reacting specifically with
thymine dimers produced by UV irradiation in double- or single-stranded
DNA.
Positive and negative control slides were included in all tests.
5.3.7. Morphological detection of apoptosis
One H&E section from each subject's 4 sites of the apoptosis study was quantified
for sunburn/apoptotic keratinocytes. Sunburn cells were identified as epidermal cells
with shrunken eosinophilic cytoplasm and a condensed nucleus (figure
5.5c,d)(Chl.6.2.3).
5.3.8. Quantification ofpositive cells (H&E and IHC)
For analysis of the staining results and preparation of images a multi-colour
microscope (Leitz), Q imaging monochrome camera and Q Capture Pro computer
software (Media Cybernetics, UK) were used. Positive and negative cells were
counted at high magnification using a x40 objective lens. Following IHC staining
cells were classed as positive if they showed uniform dark brown nuclear staining
(figure 5.5g,h,k,l,o,p,s,t). All cells were separately counted with the aid of Photoshop
5.5 and a grid (Adobe corporation, San Jose, California), the Photoshop 'pencil tool'
was used to mark each cell as it was manually counted. In this way a permanent
record of the counted cells was retained. Counting was performed by three blinded
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observers for the apoptosis study and two blinded observers for the DNA damage
study. The mean number and percentage ofpositive cells per high power field was
calculated for each section.
5.4. Results
5.4.1. Exogenous NO causes a moderate reduction in apoptosis 24 hours
after UVB exposure compared with vehicle control
To study the effect of physiologically relevant concentrations of exogenous NO on
UVB-induced keratinocyte apoptosis, Ze-NO donor was applied two hours before
and eight hourly after exposure to 2MED UVB. Apoptosis was quantified using two
methods:
• Morphological changes on H&E sections (sunburn cells).
• Presence of activated Caspase 3.
Both methods of apoptosis quantification suggested that exogenous NO-induces a
moderate reduction in keratinocyte apoptosis when assessed 24 hours following
UVB exposure (figure 5.2 a & b, figure 5.4).
• H&E (% positive apoptotic keratinocytes/HPF) - aqueous cream only 0.04 ±
0.03, aqueous cream + 2MED 4.92 ± 3.06, NO only 1.28 ±2.13, NO +
2MED 2.72 ±2.91.
• Activated caspase 3 (% positive apoptotic keratinocytes/HPF) - aqueous
cream only 0.13 ± 0.19, aqueous cream ± 2MED 4.87 ± 3.46, NO only 0.92 ±




aqueous cream aqueous cream
+ 2MED
Caspase
aqueous cream aqueous cream
+ 2MED
NO + 2MED
a) H&E morphological changes b) activated caspase 3 positive keratinocytes
Figure 5.2 Percentage apoptotic keratinocytes per highpowerfield ofhuman epidermis 24 hours post
exposure to 2MED UVB, in the presence or absence ofexogenous NO a) H&E morphological
changes, b) activated caspase 3 positive keratinocytes
Boxplots represent median and interquartile range, 'maximum andminimum values, • mean, n=7.
5.4.2. A reduction in stable p53 is observed in the presence of exogenous
NO 24 hours post 2MED UVB exposure compared with vehicle control
In addition to investigating the effects of exogenous NO on UVB-induced
keratinocyte apoptosis, I was also interested in the effects ofNO on the accumulation
of stable p53. Biopsies taken 24 hours after 2 MED UVB, in the presence or absence
ofZe-NO donor, were stained for the presence of stable p53. The changes in p53
accumulation mirrored those of keratinocyte apoptosis. If exogenous NO was present
for two hours before and for 24 hours after 2MED UVB, a reduction in the
accumulation of stable p53 was observed (figure 5.3 & 5.4). This would suggest that
exogenous NO has an anti-apoptotic role following UVB exposure which is related
to a reduction in the accumulation of stable p53. A decrease in stable p53 will lead to
a reduction in cell cycle arrest and consequently apoptosis.
• P53 (% p53 positive keratinocytes/HPF) - aqueous cream only 0.01 ± 0.02,





aqueous cream aqueous cream
+ 2MED
NO + 2MED
Figure 5.3 Percentage ofp53 positive keratinocytesper high powerfield ofhuman epidermis 24
hourspost exposure to 2MED UVB, in thepresence or absence ofexogenous NO
Boxplots represent median and interquartile range, *maximum andminimum values, • mean, n=7.
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Aqueous cream Ze NO Aqueous cream Ze NO
Apoptosis + UVR + UVR
study ^ ^aS53» h - v r ' ;Jl BKt t?(v m?-aV UMmSSi
DNA damage/repair
study
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Figure 5.4 H & E and immunohistochemical staining ofskinfollowing topical application ofZe-NO
and control in the presence or absence ofUVR, apoptosis and DNA damage/repair studies (x40)
c reveals 'sunburn cells' with shrunken eosinophilic cytoplasm and a condensed
nucleus, g & h reveal caspase positive cells in brown, k & I reveal p53 positive cells
in brown. o,p,s and t reveal CPD positive cells in brown.
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5.4.3. No significant difference was found between data from three
independent blinded observers
In the apoptosis/p53 study positive and negative keratinocytes in all sections from all
four sites of each subject were counted by three individual blinded observers. When
using such IHC techniques variability in the staining of different cells, in addition to
variability in interpretation of results by different observers, is well documented.
Despite the opportunities for methodological variation, ANOVA revealed no























Aqueous cream only UV + aqueous cream Zeolite NO only Zeolite NO + UV
Figure 5.5Comparison ofdata from three independent blinded observersfor quantification of
apoptotic keratinocytes on H&E morphology, activated caspase 3 andp53 positive cells
Mean % positive cells/high powerfield ± SEMof 7 subjects are shown.
5.4.4. No difference was observed between exogenous NO or vehicle in
CPD positive epidermal keratinocytes 30 hours post 2MED UVB
In view of the reduction in keratinocyte apoptosis observed in the presence of
exogenous NO, I wished to explore whether NO influences DNA damage or repair
processes following UVB. Ze-NO donor and vehicle control were applied to human
skin two hours before, and eight hourly for 30 hours after, 2MED UVB. Biopsies
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were taken from an irradiated and unirradiated site for both Ze-NO donor and vehicle
control at 15 minutes (maximal DNA damage) and 30 hours (50% DNA repair)
following UVB (figure 5.1). No significant difference in DNA damage was observed
between Ze-NO donor and vehicle control at either 15 minutes or 30 hours following
UVB (figure 5.4 & 5.6).
• 15 minutes (% KTM53 positive keratinocytes/HPF) - aqueous cream +
2MED 83.44 ± 10.78, NO+ 2MED 76.11 ± 15.79
• 30 hours (% KTM53 positive keratinocytes/HPF) - aqueous cream + 2MED
71.05 ± 13.91, NO + 2MED 62.27 ± 23.76
It is interesting to observe that 30 hours following UVB, a time by which one would
expect 50% ofDNA repair to have taken place, greater inter-individual variation in
the number of keratinocytes expressing DNA damage was seen in skin treated with
Ze-NO than that treated with vehicle control. This data would suggest that NO may


















15(Tins NO + 2MED SQhrs NO + 2MED
Figure 5.6 Percentage ofCPDpositive epidermal keratinocytesper high powerfield 15 minutes and
30 hours post exposure to 2MED UVB, in the presence and absence ofexogenous NO
Boxplots represent median and interquartile range, 'maximum andminimum values, • mean, n=10.
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5.4.5. Exogenous NO donor alone (unirradiated) causes no apoptosis or
DNA damage
It is important to note that neither Ze-NO or aqueous cream resulted in any DNA
damage in unirradiated skin (figure 5.7).
15mins aqueous 15mins NO onty 30hrs aqueous 30hrs NO crib/-
creamonfy creamonty
Figure 5.7 Percentage ofCPD positive epidermal keratinocytesper high powerfield 15 minutes and
30 hours post application ofexogenous NO and control, unirradiated (n=10)
5.4.6. Inter-individual variation in DNA repair is observed at 30 hours post
2MED UVB, despite controlling for skin type and MED
Maximum DNA damage in the form of CPDs is observed within 15 minutes of
exposure to UVB. Thirty hours following UVB exposure one would expect 50% of
CPD repair to have taken place in epidermal keratinocytes(Young et al., 1996). Skin
biopsies were taken both 15 minutes and 24 hours following 2MED UVB in the
presence and absence of a Ze-NO donor. A percentage change in the percentage of
CPD positive keratinocytes per high power field was calculated as a measure of
effective CPD repair 30 hours following UVB. No significant difference in the mean
number ofCPD positive keratinocytes was observed 30 hours following UVB
between Ze-NO (11.53 ± 43.31) and vehicle control ( 13.49 ± 20.05) treated sites,
however the presence ofZe-NO induced a wide inter-individual variation in the
amount ofCPD repair (figure 5.8).
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Figure 5.8 Percentage ofpercentage CPD positive epidermal keratinocytes per highpowerfield
repaired 30 hours post exposure to 2MED UVB, in the presence or absence ofexogenous NO
Boxplots represent median and interquartile range, 'maximum andminimum values, • mean, n=10.
5.5. Discussion
The experiments performed in this chapter represent the first in vivo study designed
to determine the role ofphysiological concentrations of exogenous NO on
keratinocytes in human skin in vivo following UVB exposure. The major outcome
measures were quantification of epidermal keratinocyte:
• Apoptosis
• Accumulation of stable p53
• DNA damage/repair in the form ofCPDs
A concentration and application frequency of inert stable NO donor(Mowbray et al.,
2008) was used which induced comparable erythema to that observed in human skin
24 hours after 0.75MED UVB (figure 6.3). The importance in pursuing translational
in vivo clinical research when studying the biological role ofNO is enormous in view
of the pleiotropic nature of this free radical. All investigations ofNO need to be
performed in situations which are as close to the normal in vivo biological set-up as
possible, in order to formulate solid hypotheses as to the actual role of this 'double
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edged sword' in vivo. In addition to adding weight to hypotheses regarding the role
ofNO following UVR exposure in normal human skin, the data that is presented in
this chapter is also useful for those studying the potential uses of exogenous NO or
its metabolites as a topical treatment. NO donors are already in use clinically in
various forms such as: glyceryl trinitrate (GTN) in relief of acute angina, GTN
ointments for anal fissures and transdermal patches in heart failure and chronic
angina. Potential future uses of topical NO-related products include:
antimicrobial(Weller et al., 1998), vasodilatory in Raynaud's disease(Tucker et al.,
1999), wound healing particularly in diabetics(Weller and Finnen, 2006a), and
antithrombotic as a coating for stents, extracorporeal circuits and catheters used in
interventional cardiological procedures, surgery and renal replacement therapy and
catheters(Miller and Megson, 2007a).
The experiments presented in this chapter demonstrate that physiological
concentrations of exogenous NO protect against UVB-induced epidermal
keratinocyte apoptosis 24 hours following exposure to 2MED (figure 5.2 a & b). This
observation was made using two different objective methods of apoptosis
quantification, suitable for use in paraffin embedded skin sections, both are
recognised as reproducible methods in comparison with other limited options(Baima
and Sticherling, 2002). Apoptosis is a continuous process and not always
synchronous, each method of quantification assesses a different stage in this process
and in some instances cells indicated by particular assays may not be the same. For
example, the change in nuclear morphology often does not coincide with the
appearance of detectable DNA strand breaks in cells(Willingham, 1999). The most
specific assay, and one which was chosen for use in these experiments, is perhaps the
oldest, the detection of nuclear morphological shape changes, and in the case of
keratinocytes the presence of 'sunburn cells'(DANIELS, Jr. et al., 1961). This assay
has advantages when used in the context of in vivo research where many
uncontrollable biological variables exist, it is an assay which shows great
reproducibility between observers, as was demonstrated in this study (figure 5.5).
The second method for quantification of apoptosis which was employed is the
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quantification of active caspase-3. Cysteine proteases called caspases are the
mediators of the execution phase of apoptosis, caspase-3 is regarded as a central
player in this process and is the most widely studied caspase.
Mirroring the effects ofNO on apoptosis, exogenous NO induced a reduction in the
accumulation of stable p53 in epidermal keratinocytes 24 hours after exposure to
2MED UVB, when compared with vehicle control (figure 5.3). Although again not
reaching significance, I regard these results as being informative in guiding my
hypotheses. Assays which employ IHC staining, such as the one used in this
experiment, have both advantages and disadvantages. Advantages include: cost,
labour and preservation ofmorphological function. Disadvantages include: problems
related to sensitivity of the antibody used, dilutions, fixation artefacts, differences in
methods of evaluation and inter-observer variability(Chadwick et al., 1995;Kay et
al., 1996). The many factors leading to the potential for variability with IHC are
difficult to fully control for, in addition when performing in vivo invasive procedures
in man subject numbers tend to be limited. This recognised potential of variability
increases the importance of the observation that the results from three independent
blinded observers were reproducible (figure 5.5). Published literature supports this
finding, data suggests that variance within an institution is small, where criteria are
likely to be agreed by all observers. Difficulties arise when one tries to make
comparisons of p53 immunohistochemistry between institutions(Kay et al., 1996).
In the first phase of the experiments presented in this chapter 'apoptosis study', a
moderate reduction was observed in both keratinocyte apoptosis and stable p53
accumulation if exogenous NO is present before and for 24 hours after UVB
exposure. This reduction was not found to be significant when compared to the
control situation. Despite this lack of significance I believe these results are
important in guiding our hypotheses regarding the biological actions ofNO. When
interpreting these results one must not forget the difficulties in performing invasive
in vivo clinical studies with the obvious limitations on subject numbers, in addition to
the complexities of individual biological variation. Ofnote the absence of a
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significant increase in keratinocyte apoptosis and p53 accumulation, in samples
exposed to exogenous NO both in the presence and absence ofUVR exposure, is an
important finding if exogenous NO is to be considered as a potential therapeutic
topical application.
The data presented from the 'apoptosis study' leads me to hypothesise that NO is
acting anti-apoptotically in human skin post UVB exposure, I would suggest that a
reduction in the accumulation of stable p53 in the presence of exogenous NO is
playing a role in this process. p53 has numerous vital cellular functions: gene
transcription, DNA repair, cell cycle control, genomic stability and apoptosis. In
contrast to the data presented in this chapter, high NO concentrations have been
found to induce WT p53 accumulation(Forrester et al., 1996;Ho et al., 1996), once
again this highlights the importance of using physiologically relevant concentrations
ofNO which in turn should lead to the most biologically relevant hypotheses. The
process ofDNA damage induces the accumulation of p53, a sufficient accumulation
ofnormal p53 will result in a detectable increase in p53 seen on IHC staining. The
picture is a little more complicated however, as mutant p53 is more stable than WT
and can also stain positively. Additional reasons for positive p53 include functional
or conformational abnormality in the protein not detectable at the gene level, and the
binding of the protein product to other molecules(Kay et al., 1996). The data
presented in this chapter demonstrates a corresponding reduction in apoptosis and
p53 in the presence of exogenous NO, hence I would suggest that the majority of the
reduction in stable p53 represents a reduction in the accumulation of active p53.
The reduction in apoptosis and p53 seen in the first phase of experiments 'apoptosis
study' led me to question the role ofNO in DNA damage/repair. Is NO resulting in:
• A reduction in the number of epidermal keratinocytes suffering from
significant DNA damage?
• An increase in DNA repair within epidermal keratinocytes?
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Either scenario would result in less p53 accumulation and therefore less apoptosis.
Alternatively, is NO having more deleterious consequences by inhibiting the
important regulatory process of p53 up-regulation and apoptosis, thus allowing the
persistence ofDNA damaged cells with an increased risk ofmutagenesis? I
endeavoured to answer these important questions by performing a second phase of
experiments, designed to examine the role of exogenous NO in DNA damage/repair
processes following UVB exposure. No significant difference in maximal DNA
damage was observed between keratinocytes exposed to UVB in the presence of
exogenous NO or control (figure 5.6).
As has been the experience ofmany other researchers, the assessment ofDNA
damage in keratinocytes is not without its difficulties, despite it being a subject
which has received widespread attention for many years. Firstly, the actual rate of
repair ofUV induced DNA damage is widely debated and published figures for a t\n
of repair ofCPD PPs ranges from 40-50% removal within 1 hour(D'Ambrosio et al.,
1981;Reusch et ah, 1988) to a t\a of 33.3 hours(Young et ah, 1996), with one group
suggesting that almost complete removal ofCPDs can take up to 72 hours after
exposure to as little as 1.2MED(de Winter et ah, 2001). Some of these variations can
be explained by differing methods ofCPD quantification and experimental protocols.
33.3hrs is the CPD fi/2 demonstrated by the first study to use subjects with well
defined skin types I and II, directly comparable to the skin types of our subjects, this
study also used a reasonable sample size. These observations prompted me to choose
30 hours as the time point for measuring DNA repair in the experiments presented in
this chapter(Young et ah, 1996).
Both UVA and UVB have been implicated in the pathophysiology ofNO in the
response ofhuman skin to UVR. UVB induces the majority ofDNA damage with
CPD formation in human skin peaking at wavelengths near 300nm(Chadwick et ah,
1995;Freeman et ah, 1989). Snellman et al., found mean levels ofCPDs following
NB UVB exposure (31 lnm) to be comparable to those induced by BB UVB (295-
315nm)(Snellman et ah, 2003). UVR has been used to treat various skin diseases for
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many years. There has been a recent increase in the use ofNB UVB to treat:
psoriasis, vitiligo and atopic dermatitis, this follows evidence suggesting that it is
more therapeutic than BB UVB(Coven et al., 1997;Walters et ah, 1999).
Interestingly Kunisada et al., have recently published work suggesting NB UVB
induces more carcinogenesis than BB UVB(Kunisada et ah, 2007). Taking all these
factors into account, coupled with the established in vivo murine data(Weller et ah,
2003), and the practicality of use of our departmental UVR sources for the proposed
experimental protocol, a NB UVB source was used for the studies ofboth apoptosis
and DNA damage/repair.
Interestingly, minimal inter-individual variation was observed in the maximum
percentage ofCPD positive cells (15 minutes post UVR), in the presence of either
NO donor or vehicle control (figure 5.6). In contrast, although no significant
difference was observed in the reduction ofCPD positive keratinocytes at 30 hours
post exposure (50% repair), skin exposed to UVB in the presence ofNO
demonstrates much greater inter-individual variability in CPD positive keratinocytes
at 30 hours than at 15 minutes (figures 5.6 & 5.8). This observed inter-individual
variability is not seen in control samples (figure 5.6 & 5.8). Inter-individual
variability in DNA repair kinetics is a widely recognised phenomenon(Bruze et ah,
1989;Bykov et ah, 1999;Sheehan et ah, 2002;Young et ah, 1996). Bruze et al., found
that there was significant inter-individual variation in thymine dimer yield but that
this was not related to erythemal response(Bruze et ah, 1989). Similarly Young et al.,
revealed a wide variation in CPD repair following solar simulated radiation
exposure, this variation was not related to differing skin types(Young et ah, 1996).
Bykov et al., report findings similar to those of our study, they observed an inter-
individual variation in DNA damage after 2MED UVR of six-fold, this variation
increases to 20 fold when DNA repair is considered(Bykov et ah, 1999). There
remains no strong data that suggests a relationship between skin type or erythemal
response and CPD accumulation. Some insight has however been provided by
Sheehan et al., who used single exposure data (0.65 and 2 MED) to demonstrate that
CPD accumulation is related to the physical dose (J/cm2) ofUVR and is independent
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of skin type(Sheehan et al., 2002). When investigating DNA repair kinetics, Bruze et
al. made the interesting observation that repair rates ofCPDs in vivo in human skin
are faster than those of cultured human keratinocytes or fibroblasts in vitro{Bruze et
al., 1989). This observation reinforces the importance of translational clinical
research in human subjects when one is studying the effects ofNO in DNA
damage/repair.
Aware of the wide variation in an individual's ability to repair DNA damaged
keratinocytes I attempted to minimise this problem by selecting for skin type I and II
subjects only, and thereafter selecting for subjects with the same MED.
Consequently, of our ten subjects eight had the same MED of 6.9 SED, two subjects
had an MED of 8.7 SED. SED is a standard measure ofUVR dose, one SED is
equivalent to an erythemal effective radiant exposure of 100J m-2 (Diffey,
2002)(Chl.6.2.2). An additional source of potential variation lies in the IHC assay
itself, maximal CPD accumulation 15 minutes following UVR exposure manifests as
very strongly positive and uniform staining in all affected keratinocytes (figure 5.4
o&p). In contrast, 30 hours after UVR exposure, when approximately 50% ofCPD
repair has taken place, one would envisage keratinocytes at varying stages ofCPD
repair. This period of 'mid-repair' is manifest on IHC staining as keratinocytes which
exhibit variable degrees of staining (figure 5.4 s&t), thus making accurate
quantification more variable, both in NO and control treated specimens. Despite the
potential methodological variation discussed, the degree of variation in DNA repair
between individuals which was observed in the presence of exogenous NO, would
suggest that NO may affect the DNA repair kinetics in some subjects. Exploration of
such a hypothesis would require further experiments with greater subject numbers.
Some of the inter-individual variation in DNA repair may be explained by an
individuals NO stores, already present as NO-related products stored in the skin and
in sweat on the skin surface. Both skin and sweat nitrososepices are sources ofUVR-
induced enzyme-independent NO production, and both are influenced by an
individuals plasma concentration ofNO-related products (Ch4.4.6). Plasma
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concentration ofNO-related products is itself dependent on an individuals dietary
NO3" ingestion(Lundberg and Govoni, 2004). One option of further controlling for
inter-individual variation would be to introduce a NO3" controlled diet to each subject
prior to commencing the apoptosis and DNA damage/repair experiments, this would
improve control of inter-individual variation in skin stores ofNO-related products.
An additional factor which may serve to minimise inter-individual variation may be
provided by tighter determination of an individuals MED, such that even closer
matching ofMEDs can be achieved. Damian et ah, suggest calculating the melanin
index of each subject using a reflectance melanin meter, following this one can
achieve tighter determination of the MED around narrower increments, with test
doses clustered around the MED(Damian et al., 1997). Having determined each
individuals MED, I would still advocate selection of subjects with the same MED,
thus ensuring equal biological and physical doses ofUVR are administered, and
hopefully minimising inter-individual variability.
With a variety of factors potentially influencing inter-individual variability in DNA
repair following UVR exposure, it is difficult to make solid hypotheses regarding the
role ofNO in this process. As indicated previously, such invasive experiments
performed in human subjects always result in small subject numbers who each bring
with them their own personal biological variability. This should not detract from the
importance of such experiments and the guidance that they offer in directing future
research. Importantly, in the case of exogenous NO, no significant increase in DNA
damage was seen on its topical application in the presence or absence ofUVR.
Further work in this area needs to be directed towards the potential subtle but
important effects of differing concentrations ofNO on apoptosis and DNA
damage/repair following UVR. Such experiments should include NO both in the
form of endogenous stores ofNO-related products, or exogenous NO as used in these
experiments. As has been highlighted throughout this discussion, it is essential that
this work is directed towards in vivo clinical studies in order to fully elucidate the









6. CHAPTER 6 - NO and UVR-INDUCED UPREGULATION OF
ARGINASE IN HUMAN SKIN
6.1. Introduction
The skin is the largest organ in the human body and is a primary target for many
environmental stimuli in particular UVR. As has been demonstrated in the previous
chapters, much evidence now exists to suggest that NO plays a major role in UVR-
induced cutaneous effects. All three NOS enzymes have been shown to exist in
human skin in varying amounts. Enzyme-dependent NO release following UVR is
secondary to the upregulation of iNOS, which starts eight to ten hours after UV
exposure and reaches a maximum at approximately 24 hours(Kuhn et al.,
1998;Suschek et al., 2001b). Enzyme-dependent NO is the major mediator ofUV
erythema in man(Rhodes et al., 2001). NO can also be released by enzyme-
independent mechanisms, UVR induces the photolysis of NO-related products
stored in human skin, this release occurs within 20-30 minutes ofUVR
exposure(Paunel et al., 2005) (Ch 4.4.6).
NO is a free radical which is well known for its pleiotropic actions, the actions ofNO
are determined by the concentration ofNO, the target cell and the microenvironment.
The biphasic nature ofNO is exemplified by the role it plays in both inflammation
(Chl.4.2) and apoptosis (Chi .6.3.4). In the experiments described in the preceding
chapters the NO environment has been manipulated by the use of an inert topical NO
donor (Ze-NO), all experiments were performed using physiologically relevant
concentrations ofNO, in attempt to best mimic the normal biological situation.
Varying the concentration ofNO in human skin has the potential to cause variable
effects on biological processes, such as apoptosis and inflammation. In view of the
dramatic effects that differing NO concentrations can have on human skin, it is likely
that the human body has an in-built mechanism for the control ofNO generation and
concentration in human skin.
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NO is synthesised from L-arginine by all three NOS isoenzymes, appropriate iNOS
activity following UVR-induced iNOS upregulation depends on the availability of L-
arginine, in addition to expression and activity of CATs, which allow L-arginine
transport into cells (Chi.3.2). It has been shown that in cytokine activated endothelial
cells, L-arginine supply at physiological levels can restrict eNOS activity(Suschek et
ah, 2003a). Evidence exists of a tight link between iNOS and the urea cycle, arginase
competes for L-arginine as a substrate which it hydrolyses to ornithine and urea as
part of the urea cycle (figure 6.8). Arginase has been shown to be effective in down
regulating NO production(Mori and Gotoh, 2000).
6.2. Aims
The aim of this study was:
• To further investigate preliminary findings which suggest a feedback control









All methods common to more than one study are detailed in Chapter 2.
6.3.1. Study volunteers
Eight healthy volunteers participated in the study, age range 21-50 years, 1 male.
6.3.2. UV source
The UVB source used was a Waldmann UV 801 BL unit (Waldmann, Villingen-
Schwenningen, Germany) which contains a bank of ten TL 20W/01RS fluorescent
lamps (Philips, Eindhovan, Holland). TL 20W/01RS lamps emit a narrow peak
around 31 lnm exclusively. Using this apparatus 1SED ofUVR is delivered over 30
seconds to a 10cm" area (10mJ/0.33mW) of skin at a distance of 10cm from the
irradiating bulbs (figure 6.4).
6.3.3. Preparation and application of topical NO donors
Ze-NO (33% wt/wt) was used as an NO donor. This is an inert topical NO donor
which 1 have considerable experience using(Mowbray et ah, 2008). At the time of
each application Ze-NO powder was mixed with aqueous cream BP® and applied
immediately to an area on the lower back (figure 6.2). Ze-NO was reapplied




Each volunteer attended the department a total of five times covering four separate
days:
Day 1 - graded doses of UVB to volar forearm for determination ofMED.
Day 2, 0 hours - reading ofMED, irradiation of lower back and Ze-NO application.
Day 2, 1 hour - 20 tape strips from each of 5 sites on the lower back.
Day 3-20 tape strips from each of 5 sites on the lower back.
Day 14-20 tape strips from each of 5 sites on the lower back.
Five 9cm by 3cm strips each I cm apart were marked on the lower back (figure 6.2 &
6.3).
• Strip 1 - unirradiated
• Strip 2 - 0.75MED
• Strip 3 - 1 MED
• Strip 4 - 2MED
• Strip 5 - 33% Ze-NO
Ze-NO was removed with distilled water followed by an alcohol swab (Alcotip, UHS
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Figure 6.2 Diagrammatic representation of treatment and tape strip sites oflower backfor each
subject
Immadiately post UVR 1 day post UVR
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1 hour post UVR 13 days post UVR




At 1 hour, 1 day and 13 days post treatment, 20 tape strips were taken from each site
(indicated by O figure 6.2). Tape stripping was performed as described in Ch2.3.1,
figure 2.2.
6.3.6. Amino acid analysis
The concentration of free amino acids (L-ornithine, L-citrulline and L- arginine)
were analyzed on tape strip layer 10 using HPLC. All amino acid concentrations
were normalised to the protein concentration of the strip. All tape strip analysis was
kindly performed by colleagues at Estee Lauder Companies, Oevel, Belgium.




6.4.1. L-arginine levels in the epidermis do not change in response to UVR
or exogenous NO
No significant changes were observed in L-arginine levels in the epidermis, as
measured by tape striping, following exposure to UVR. A moderate increase in L-
arginine with increasing doses of UVR was seen at two weeks following UV
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6.4.2. L-citrulline levels in the epidermis decrease two weeks after exposure
to 2MED UVR
Similar to L-arginine, no significant change was seen in L-citrulline levels in the
epidermis following UVR at doses of 0.75 and 1 MED, or following exogenous NO
donor application. A significant decrease in L-citrulline was observed between
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Figure 6.6 L-citrulline concentration as measured from IOf' tape strip post UVR or exogenous NO
application (n=8)
p<0.05 2MED at 1 hour/1 day compared with 2 weeks
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6.4.3. A significant dose dependent increase in L-ornithine levels is seen in
the epidermis in response to UVR and exogenous NO
Significant dose dependent increases in L-ornithine levels in the epidennis were
observed between samples taken at one hour or one day post UVR and those taken
two weeks post UVR (figure 6.7). A similar significant increase was seen in L-
ornithine two weeks following the application ofZe-NO. Such an increase in L-
ornithine is assumed to be secondary to up regulation of arginase, which hydrolyses
L-arginine to L-ornithine as part of the urea cycle (figure 6.8).
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Figure 6.7 L-ornithine concentration as measured from 10" tape strip post UVR or exogenous NO
application (n=8)
p<0.05 2 week values compared with I hour/ 1 day
6.5. Discussion
As has been shown in the preceding chapters, NO is a key player in the cutaneous
response to UVR. L-arginine is a common substrate for iNOS and arginase, resulting
in NO + L-citrulline or urea + L-ornithine respectively. This experiment provides
evidence of a dose dependent increase in L-ornithine in the stratum corneum of
human skin 13 days following exposure to UVR. In addition, application of a topical
NO donor revealed a similar increase in epidermal L-ornithine, which was
comparable to that induced by 0.75MED UVB. These findings provide evidence that
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the increase in NO and iNOS following UVR is mirrored by an upregulation in
arginase activity, we postulate that this offers an important regulatory feedback
mechanism between iNOS and arginase.
Ze-NO was used as a topical NO donor, it is known that this NO donor releases
relatively low concentrations of NO(Wheatley et al., 2006). Twenty four hours after
topical application of 33% Ze-NO to sun protected human skin, erythema is induced
which is equivalent to that seen 24 hours following 0.75MED UVB (figure 6.3).
Interestingly, the increase in arginase activity, as measured by L-ornithine
concentration, was not accompanied by a corresponding increase in the other main
amino acids in the urea cycle in particular L-citrulline. L-citrulline is the subsequent
amino acid in the urea cycle after L-ornithine and also a by product of the generation
ofNO by iNOS from L-arginine (figure 6.8). I present a number of hypotheses to
explain how arginase plays an important role in the L-arginine-NOS feedback loop
without concomitant fluctuations in L-citrulline.
The process of tape stripping enables sampling of the superficial epidermal layer, the
stratum corneum (figure 2.3a). UVB radiation penetrates to, and exerts its effects on,
all layers of the epidermis. The mean epidermal transit time for a keratinocyte to pass
from the basal layer of the epidermis to the stratum corneum is 25 days(Weinstein et
al., 1984). In taking tape strip samples 13 days following UVR we assume that we
will be sampling some keratinocytes that were in the basal layer at the time of
irradiation with the majority having been in the lower 1 /3rd of the epidermis, the
suprabasal squamous/spinous cell layers (figure 2.3a). One simple explanation for
the findings in this experiment are that the cells which have been sampled by tape
stripping were arrested at a specific point in the urea cycle after L-ornithine
formation but before its conversion to L-citrulline.
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The constitutive NOS isoenzymes eNOS and nNOS maintain homeostatic levels of
NO, however high output NO formation as occurs following UVR requires iNOS
upregulation. Effective NO generation from iNOS is absolutely dependent upon the
delivery of its substrate L-arginine into the cell by CATs. The CAT family is
composed of four known isoforms, CAT 1, CAT2A, CAT2B, and CAT-3. CAT-1 is
expressed ubiquitously and is present in all skin cells, CAT-2 is expressed strongly in
the liver and has been isolated in primary human keratinocytes and dermal
endothelial cells, where its expression is up regulated within 24 hours of a Thl
cytokine challenge(Schnorr et ah, 2003). CAT-3 is expressed specifically in the
brain(Mori and Gotoh, 2000). The cationic amino acids transported by this system
include L-arginine, L-lysine and L-ornithine, they share the same substrate
specificity, therefore CAT competition (via lysine/ornithine) strongly inhibits iNOS
and arginase activity(Suschek et ah, 2003a) (figure 6.8). UVR induces an increase in
TNFa, a Thl cytokine, this increase is maximal 24 hours post UVR and may be of
importance in inducing CAT-2 expression and allowing adequate delivery of the
substrate L-arginine into the cell. Although the majority of CAT-2 expressed is
probably transporting L-arginine into the cell some of the increase in L- ornithine
induced by UVR maybe secondary to this increase in CAT-2 expression.
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Figure 6.8 The Urea Cycle (copy offigure 1.3 page 7)
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Arginases compete with iNOS for the common substrate L-arginine, this enzyme
exists as two isoforms: arginase-1, a cytosolic inducible type, and arginase-2, a
mitochondrial enzyme. Bruch-Gerharz et al., found that in normal human skin
arginase 1 is weakly expressed throughout the epidermis(Bruch-Gerharz et al., 2003).
In contrast, Wohlrab et al. found arginase concentration to be higher in basal
keratinocytes than in the stratum corneum, they found no arginase in the spinous
layer (Wohlrab et al., 2002). Li et al., have shown that in bovine endothelial cells
production of L-ornithine increased in direct proportion to cellular arginase
activity(Li et al., 2001). The data presented in this chapter suggests that considerable
arginase activity is present in the epidermal layers of human skin, the activity of
epidermal arginase is up regulated by UVR, manifesting as an increase in L-
ornithine.
Intracellular compartmentalisation of arginases has an important implication for
arginine metabolism in mammalian cells, and may also help to explain the observed
absence of an increase in L-citrulline despite an increase in L-ornithine. Such
compartmentalisation of arginases has been demonstrated by Li et al. who have
described the co-localisation of arginase 1 with ornithine decarboxylase in the
cytosol, in addition to the co-localisation of arginase 2 and ornithine
aminotransferase in mitochondria(Li et al., 2001). Such intracellular
compartmentalisation of arginases may itselfprevent further conversion of L-
ornithine down subsequent pathways such that a rapid increase in L-ornithine is seen
as a consequence of high production states, as seen post UVR.
An additional cycle exists between L-citrulline and NO, the 'citrulline-NO cycle',
properties of which may also help to explain the apparent low concentrations ofL-
citrulline despite an increase in L-ornithine. It has been shown in various tissues and
cells, including in vivo cultured rat macrophages, that arginosuccinate lyase and
arginosuccinate synthetase are co-induced with iNOS following cytokine
induction(Nagasaki et al., 1996). The co-induction of arginosuccinate lyase and
arginosuccinate synthetase with iNOS would ensure that the UVR induced up
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regulation of iNOS, with subsequent NO release and L-citrulline generation, does not
result in a build up of L-citrulline (figure 6.8).
Despite the complexities of the potential interactions between the different substrates
and enzymes of the urea cycle, the experiment described in this chapter shows an
impressive dose-dependent increase in L-ornithine/arginase activity following UVR,
which is mirrored by exogenous NO. Evidence exists to suggest that in rat
endothelial cells the enzyme kinetics favour arginase when up regulated relative to
NOS(Berkowitz et al., 2003).
I hypothesise that following exposure to UVA rapid enzyme-independent release of
NO takes place from human skin within 20 minutes of exposure, thereafter
upregulation of iNOS and CAT-2 (both maximal 24 hours post UVR) results in
enzymatic NO release. Consequently UVR induced cutaneous erythema develops,
and the increase in NO has an anti-apoptotic role on human keratinocytes(Suschek et
al., 1999;Weller et al., 2003) (Ch5.4.1). Subsequent to NOS upregulation arginase is
upregulated, this acts as a competitor for the common substrate L-arginine, thus
limiting NOS activity. This inbuilt control mechanism in human skin ensures that
levels of iNOS in normal human skin return to baseline by 72 hours post UVR
exposure(Kuhn et al., 1998). The data presented in this chapter provides new
evidence implicating the importance of the urea cycle in control of iNOS and NO
generation, it also provides additional evidence to underline the fundamental role of







7. CHAPTER 7 - GENERAL DISCUSSION
7.1. Summary and Conclusions
Knowledge of the physiological importance of inorganic nitrogen oxides is evident
dating back to 800AD(Binkerd and Kolari, 1975). However, a massive growth in the
interest of the biological effects ofNO was not observed until the 1980s. This
interest stemmed from the finding that NO release from smooth muscle vascular
endothelium has vasodilatory properties(Furchgott and Zawadzki, 1980a;Furchgott,
1986;Ignarro et al., 1987b). Enzyme-dependent NO generation from NOS was
described by Moncada et al. in 1993(Moncada and Higgs, 1993). Subsequently, three
different NOS isoenzymes were isolated, two consitutively expressed isoforms
(e/nNOS) and one inducible isoform (iNOS). Constitutive NOS isoforms are
regarded as providing regulatory and homeostatic functions, whereas iNOS plays a
more pathological role.
With the relative ease ofperforming IHC staining in skin biopsies, it did not take
long before all three NOS isoforms were identified in human skin(Baudouin and
Tachon, 1996;Becherel et al., 1994;Bull et al., 1996;Romero-Graillet et al.,
1996;Sakai et al., 1996;Wang et al., 1996). A number of groups went on to
demonstrate the presence of iNOS in inflammatory skin diseases: psoriasis(Kolb-
Bachofen et al., 1994;Sakai et al., 1996), atopic dermatitis(Clancy et al., 1998;Rowe
et al., 1997) and LE(Clancy et al., 1998). Since the 1980s NO has become known as
a 'double edged sword', the biological roles of this free radical are complex and
often vary according to the concentration ofNO, the target cell and the
microenvironment. This feature is demonstrated by the pleiotropic role that NO can
play in both inflammation and apoptosis. This is demonstrated well in psoriasis
where iNOS and subsequently NO are elevated in psoriatic plaques, however
arginase is also upregulated. Arginase competes with NOS for L-arginine which
145
Chapter 7
results in a relatively low elevation in NO that is sufficient to induce keratinocyte
proliferation but not differentiation(Bruch-Gerharz et al., 2003).
NO has been implicated in the cutaneous response to UVR. Inducible NOS is
upregulated following UVB exposure, expression can be demonstrated 8-10 hours
after exposure and is maximal by 24 hours(Kuhn et al., 1998). Maximal iNOS
activity corresponds with UVR-induced erythema, this erythema is abrogated by
antagonism of iNOS(Goldsmith et al., 1996). Evidence also suggests that NO plays
an anti-apoptotic role in human skin following UVR(Suschek et al., 1999;Suschek et
al., 2003b;Weller et al., 2003).
The biphasic nature ofNO highlights the importance of in vivo translational clinical
research in human subjects, in order to accurately investigate the role ofNO in the
biological situation. Academic dermatologists are well placed to perform such
research as the organ of interest 'human skin' is relatively accessible. Initial work
began by manipulation of the NO environment with the use ofNOS antagonists,
unfortunately no NOS antagonist exists that specifically inhibits individual NOS
isoforms, and is suitable for use in human subjects. This area of research was made
more complex in 2002 following the publication by Feelisch et al., of a method for
quantifying NO-related products(N03~, NO2", RSNOs) in biological
samples(Feelisch et al., 2002). It had been known for some time that NO3" & NO2"
are present in the sweat on the surface of human skin(Weller et al., 1996). With the
advent of the gas-phase chemiluminesence based method described by Feelisch et
al., NO-related products were also quantified in full thickness ex-vivo human skin
samples(Paunel et al., 2005). Paunel et al., also demonstrated enzyme-independent
release ofNO from stores ofNO-related products in human skin following UVR, this
release is maximal within 20-30 minutes of exposure(Paunel et al., 2005).
With the knowledge that NO can be produced in human skin following UVR by both
enzyme-dependent and enzyme-independent mechanisms, it became apparent that
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manipulation of the NO microenvironment using a NOS antagonist would not be
particularly useful, as this method would not fully abrogate NO production. The first
experimental chapter in this thesis (Ch3) describes experiments which were designed
to investigate the properties of two NO donors, and in particular to demonstrate the
nature ofZe-NO. I have shown that Ze-NO delivers physiologically relevant
concentrations ofNO to human skin without inducing significant inflammation. This
is an important observation as previous work by Ormerod et al., demonstrated that
acidified N02" when used as a topical NO donor induced significant
inflammationfOrmerod et al., 1999a). I suggest that NO is not as potent an
inflammatory mediator as was previously indicated, I also propose a number of
alternative mechanisms to explain the inflammation seen with acidified N02~.
With the increasing awareness that NO-related products as storage compounds ofNO
are important in NO biology, and NO-related products in human skin play a role in
UVR-induced processes, I wished to further investigate these areas. Using different
methods of sampling from human skin: sweat collection, epidermal suction blisters,
cutaneous microdialysis and full thickness skin biopsies, I have demonstrated the
presence ofNO-related products in human skin. Nitrate and N02" are the most
common NO-related products found in human skin, sweat and saliva. Consistent with
the findings of Paunel et al., 1 demonstrate that UVA exposure induces release ofNO
within 30 minutes of the onset of irradiation, as measured by in vivo cutaneous
microdialysis of the superficial vascular dermis(Paunel et al., 2005). This UVA-
induced NO release is reduced by the use of noradrenaline as a dialysate, suggesting
that the superficial dermal vasculature is important in the delivery ofNO and NO-
related products to the skin following UVA exposure. Lundberg et al, have shown
that the concentration ofNO-related products in plasma is determined by dietary
NO3" ingestion(Lundberg and Govoni, 2004). Data presented in chapter four suggests
a relationship between the concentration ofNO-related products in plasma and in the
sweat and dermis, such that the concentration ofNO-related products in human
plasma determines one third of the concentration ofNO-related products in sweat
and two thirds of the concentration ofNO-related products in the superficial dermis.
147
Chapter 7
With the knowledge that dietary NO3" influences the concentration ofNO-related
products in plasma, and the evidence that this in turn may influence the concentration
ofNO-related products in human skin, I postulate that dietary NO3" may influence an
individuals cutaneous response to UVR.
In vivo murine and in vitro human data suggests that NO has an anti-apoptotic role in
human skin following UVR exposure(Suschek et al., 1999;Suschek et ah,
2003b;Weller et ah, 2003). The importance of in vivo clinical research in the context
ofNO has been eluded to constantly throughout this thesis; this is of particular
relevance when considering the role ofNO in apoptosis. Many authors describe both
anti- and pro-apoptotic roles for NO depending on its concentration, the target cell
and the microenvironment (Chi.4). With the use of an inert topical NO donor (Ze-
NO), which delivers physiologically relevant doses of exogenous NO, I have
demonstrated that NO causes a moderate reduction in apoptosis 24 hours after 2MED
UVB. A reduction in stable p53 was also observed in the presence of exogenous NO
24 hours after 2MED UVB. These findings suggest that NO is acting anti-
apoptotically in human skin post UVB exposure, I would suggest that a reduction in
the accumulation of stable p53 in the presence of exogenous NO is playing a role in
this process.
IfNO is acting anti-apoptotically in human skin following UVR, is it leading to:
• A reduction in the number of epidermal keratinocytes suffering from
significant DNA damage?
• An increase in DNA repair within epidermal keratinocytes?
therefore reducing p53 accumulation and apoptosis. Or alternatively, is NO having
more deleterious consequences by inhibiting the important regulatory process of p53
up-regulation and apoptosis, thus allowing the persistence ofDNA damaged cells
with an increased risk ofmutagenesis? In order to answer these questions I examined
the role of exogenous NO in UVR-induced DNA damage and repair within
epidermal keratinocytes. NO did not influence the accumulation of maximal DNA
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damage in epidermal keratinocytes following UVB. Importantly, exogenous NO
alone (unirradiated) induced no DNA damage in epidermal keratinocytes. An
increase in inter-individual variation in the ability to repair DNA damage in
epidermal keratinocytes was seen 30 hours following UVB exposure, in the presence
of exogenous NO. This finding may indicate that NO can influence the DNA repair
kinetics of epidermal keratinocytes. This remains a complex topic as inter-individual
variability in DNA repair kinetics is a widely recognised phenomenon(Bruze et al.,
1989;Bykov et al., 1999;Sheehan et al., 2002;Suschek et al., 1999;Suschek et al.,
2003b; Young et al., 1996), there remains debate as to which factors are most
important in influencing this variability.
Finally, as the evidence for NO as an important mediator in human skin increases, it
seems likely that the body has adapted its own control mechanisms to ensure
appropriate concentrations of this free radical are available. For example iNOS
upregulation following UVB exposure is maximal 24 hours after exposure, but has
returned to baseline by 72 hours. L-arginine is a common substrate for both iNOS
and arginase, resulting in the production ofNO + L-citrulline and urea + L-ornithine
respectively. I present strong data which shows that there is a significant dose
dependent increase in L-ornithine levels in the epidermis in response to UVR and
exogenous NO. This data suggests that following UVR-exposure the upregulation of
arginase acts as a negative feedback mechanism and thus contols NO production by
iNOS. This provides new evidence implicating the importance of the urea cycle in
control of iNOS and NO generation
149
Chapter 7
7.2. Future directions andfurther studies
The findings presented in this thesis demonstrate many avenues which could be
potentially very interesting and useful to follow, in order to further elucidate the role
ofNO in cutaneous physiology.
Ze-NO is a very effective NO donor, one of its most important features is that it
delivers physiologically relevant doses of exogenous NO, and is non-irritating. The
use ofZe-NO as an NO donor was vital to many of the experiments presented in this
thesis. Although relatively easy to administer, some improvements could be made to
this NO donor, which would enhance its potential use as a topical NO donor in future
experiments. At present Ze-NO powder is mixed with aqueous cream immediately
prior to application on the skin, thereafter the majority ofNO is released within the
first hour after application. An ideal topical preparation would involve simply the
application of one product, with subsequent release being more gradual and sustained
over a relatively long period of time (eg hours).
Cutaneous NO-related products are present in human skin. Evidence would suggest
that they can be influenced by dietary NO3" intake, and that they are strongly
involved in the cutaneous response to UVR. It would be interesting to take these
suggestions a step further, to determine whether controlling for/adjusting dietary
NO3" intake directly influences the concentration of cutaneous NO-related products.
This could be performed real time in vivo by measuring cutaneous NO-related
products in the superficial vascular dermis, using cutaneous microdialysis, following
ingestion of a dietary NO3" load. Alternatively, epidermal suction blisters or full
thickness skin biopsies could be used to quantify cutaneous NO-related products ,
after either controlling for or loading with dietary NO3". Other variables to consider
when studying human skin are both an individuals skin type and their tendancy to
develop erythema after UV exposure. It would be of interest to study variations in the
resting concentrations of cutaneous NO-related products in individuals of different
skin type and erythemal sensitivities, and thereafter to identify whether these factors
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influence the release ofNO from cutaneous NO-related products following UVR
exposure. Although much remains to be investigated regarding the role ofNO-
related products in normal human skin, their role in skin disease is also an important
consideration. The ability to quantify NO-related products will be very useful in
further assessing the role ofNO and NO-related products in skin diseases in which
NO has already been implicated, for example psoriasis, atopic eczema and cutaneous
lupus erythematosus.
The role ofNO in epidermal keratinocyte apoptoisis and DNA damage/repair
following UVR is always going to be difficult to study. In addition to the biological
variation that each individual brings with them to a study, many additional
experimental variables exist. These factors, coupled with the pleiotropic nature of
NO, make it vital that further research in this field is performed whenever possible in
the in vivo situation, using physiologically relevant parameters. As has been
discussed earlier, further experiments which control for an individuals dietary NO3",
and therefore their ability to produce NO by enzyme-independent mechanisms on
UV exposure, may reduce the variability between subjects. Experiments to further
elucidate the roles ofUVA, UVB and possibly more relevant solar simulated
radiation, would also further improve our knowledge of this field. Attempts were
made to control for the known biological variation in DNA repair by selecting
individuals with the same MED. These individuals exhibited a similar erythemal
sensitivity on UV exposure, and the dose ofUVR to which each individual was
exposed was the same. Improvements could be made by using tighter MED
increments, this would provide tighter determination of an individuals MED, such
that even closer matching of erythemal sensitivity could be achieved.
With all the experiments which utilized a topical NO donor, 33% Ze-NO was the
donor of choice. The concentration selected is the maximum concentration at which
Ze-NO powder can be mixed adequately with aqueous cream, and thereafter applied
to the skin in a uniform manner. An important consideration in selecting this NO
donor lies in its inert properties, in addition it provides physiologically relevant doses
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ofNO. A number ofpotentially useful topical donors exist such as S-nitrosothiol-
based topical donors, however in my experience these tend to deliver massive
concentrations ofNO which are several orders ofmagnitude higher than those seen
in the normal physiological situation. In future experiments it would be interesting to
determine whether exogenous NO has different dose-effects in the context of
inflammation, apoptosis and DNA damage, in the presence and absence ofUVR.
Finally, having discussed potential avenues for the investigation ofNO and its
relationship with inflammation and UVR in normal skin, I would like to progress to
looking at skin disease, in particular cLE. Photosensitivity is now a well-established
factor in the pathogenesis of cLE, in clinical and experimental settings, and it is
included as a discriminating factor in the revised criteria of the American
Rheumatism Association for the classification of SLE(Tan et al., 1982).
Photosensitivity occurs in 10-92% ofpatients with SLE, in 50-100% of those with
subacute cutaneous LE and in 39-89% of discoid LE(Sanders et al., 2003). In
contrast to normal skin, UVR-induced peak erythema and iNOS expression are
delayed to between three and 24 days in cLE(Kuhn et al., 1998). Excess apoptosis is
also thought to be a central event in the pathophysiology of LE, this may be due to
either reduced clearance or increased production(Pablos et al., 1999). Histologically,
the characteristic basal keratinocyte apoptosis seen in cLE produces an appearance of
'dermo-epidermal effacement' and an inflammatory infiltrate. Apoptosis exposes
epitopes on the nuclear membrane, which are presented by dendritic cells to the
immune system, and in the context of the relevant HLA types, leads to the
production of autoimmune nuclear antibodies(Caricchio et al., 2003;Gabler et al.,
2003). In summary cLE has been shown to be associated with aberrant iNOS
upregulation following UVR, in addition the hallmarks of this disease are those
which I have studied with regards to NO:
• Photosensitivity




From an experimental point of view, the disease of cLE can be induced using
artificial UV sources, this makes it an ideal disease in which to further study the role
ofNO in human skin.
7.3. Clinical implications
One of the most obvious clinical applications to stem from this thesis would be the
development ofZe-NO as an NO donor for use in the clinical setting. Topical NO
donors have already been shown to be mediators in the treatment of cutaneous fungal
and viral disease(Ormerod et al., 1999b;Weller et al., 1998), Raynaud's
phenomenon(Tucker et al., 1999), diabetic wound healing(Witte et al., 2002a),
melanogenesis(Romero-Graillet et al., 1996;Romero-Graillet et al., 1997) and the
control of keratinocyte apoptosis following UVR(Suschek et al., 1999;Suschek et al.,
2003b;Weller et al., 2003). Further work needs to done, firstly in developing a form
ofZe-NO which is easy to apply and releases sustained amounts ofNO. Secondly,
further investigation of the effects that Ze-NO has on the cutaneous response to
UVR, including dose-response studies, are necessary. If exogenous NO at
physiological concentrations is found to be reducing UVR-induced DNA damage,
and consequently keratinocyte apoptosis, one could envisage its future use in topical
sunscreen preparations.
An additional implication ofmy hypotheseses regarding the protective role of both
enzyme-independent and enzyme-dependent NO in human skin has implications for
health promotion. Should it be found that dietary NO3" does directly influence
cutaneous stores ofNO-related products, a logical progression would be to advise a




In summary, I have studied the role of 'NO as a regulator of apoptosis and
inflammation in human skin following UVR'. I present Ze-NO as a clinically and
experimentally useful NO donor which has essential non-irritating properties. I have
shown that human skin, the largest organ in the human body, acts as a store for NO-
related products both in sweat on the skin surface and in the skin itself. Evidence
suggests that these stores correlate with the concentration ofNO-related products in
plasma, which are in turn determined by dietary NO3" intake. The demonstration of
rapid enzyme-independent release ofNO from stores of cutaneous NO-related
products within 20-30minutes ofUV exposure, is likely to be important in the
cutaneous response to UVR. This rapid release ofNO bridges the time gap before the
upregulation of iNOS and enzyme-dependent NO release takes place. It seems that
NO release from human skin following UV exposure has an anti-apoptotic role,
however further work needs to be done to elucidate its effects on epidermal
keratinocyte DNA damage/repair. Finally, it is likely that the human body has an
inbuilt regulatory mechanism to ensure control ofNO production following UVR.
Evidence suggests that a competitive feedback loop exists between arginase and
iNOS for the common substrate L-arginine, this provides control over NO production
and ensures that iNOS returns to baseline levels within 72 hours ofUVR. These
findings add greatly to the knowledge ofNO and its role in human skin, in addition
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